STOCK TITAN

SS Innovations Q3 revenue falls to $6.3M; loss widens

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

SS Innovations International, Inc. (SSII) reported nine-month revenue of $31.4 million, compared with $28.0 million in 2025, while its net loss was $12.0 million versus $9.7 million. For the third quarter, revenue was $6.3 million compared with $12.8 million, and net loss was $5.7 million versus $3.7 million. Net cash used in operating activities for the nine months was $12.9 million, compared with $17.0 million.

On October 9, 2026, SSII received $20.0 million in gross proceeds from investor Growth Capital Partners, LLC, issuing a secured convertible promissory note with $21.025 million principal. The note bears 8.75% annual interest, matures 36 months after issuance, converts at 95% of the defined Market Price, and is subject to monthly investor redemptions beginning 12 months after issuance, payable in cash or shares. It is secured by SSII’s intellectual property and assets and those of SSI IP Holdings, excluding SSI-India’s assets and capital stock. SSII intends to use net proceeds for working capital and general corporate purposes. The company said existing cash resources and operating income are not expected to fund operations and business development through the next 12 months, and that these conditions raise substantial doubt about its ability to continue as a going concern.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month revenue was $31.4 million versus $28.0 million in 2025.
  • Moderate pointOperating cash use was $12.9 million versus $17.0 million.

Negative

  • Major pointSubstantial doubt cited about continuing as a going concern within 12 months.
  • Moderate pointThird-quarter revenue was $6.3 million versus $12.8 million in 2025.
  • Moderate pointNine-month net loss was $12.0 million versus $9.7 million in 2025.

Filing Explained

At September 30, cash and cash equivalents were $8,113,767, restricted cash was $10,121,321, and total debt was $18,139,143.

Form 10-Q is an unaudited quarterly report; this one reports that SS Innovations had 200,488,427 common shares outstanding on September 30, 2026, versus 194,165,141 on December 31, 2025, so a fixed holding represents a smaller percentage of the larger share base, absent offsetting changes.

The company reports restricted cash in fixed deposits subject to withdrawal restrictions, separate from cash and cash equivalents.

Nine-month revenue $31.4 million Nine months ended September 30, 2026; $28.0 million for the same period in 2025.
Nine-month net loss $12.0 million Nine months ended September 30, 2026; $9.7 million for the same period in 2025.
Third-quarter revenue $6.3 million Three months ended September 30, 2026; $12.8 million for the same period in 2025.
Third-quarter net loss $5.7 million Three months ended September 30, 2026; $3.7 million for the same period in 2025.
Net cash used in operating activities $12.9 million Nine months ended September 30, 2026; $17.0 million for the same period in 2025.
Gross proceeds $20.0 million Financing completed October 9, 2026.
Convertible note principal $21.025 million Note issued October 9, 2026, at a $20.0 million purchase price.
Interest rate 8.75% per annum Secured convertible note issued October 9, 2026.
substantial doubt financial
"These conditions raise substantial doubt about the Company’s ability to continue as a going concern"
secured convertible promissory note financial
"issued a secured convertible promissory note to Growth Capital Partners, LLC"
original issue discount financial
"This note carries an original issue discount of $1,000,000"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
deferred payment arrangement financial
"The Company also sells surgical robotic systems under deferred payment arrangements"
sales-type lease financial
"net investment in sales-type leases"
A sales-type lease is a contract where the party that owns an asset (the lessor) effectively sells it to a customer but keeps the right to receive lease payments, recording the transaction as a sale up front and then recognizing interest income over time. Think of it like a store that sells you a car on finance: the store books the sale immediately but still collects payments and interest, so profits and the asset’s removal from the balance sheet occur sooner. For investors this changes when revenue and profit show up, alters reported assets and liabilities, and affects measures like return on equity and cash flow timing.
performance obligation technical
"Each of these products and services is a distinct performance obligation"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did SSII report for the first nine months of 2026?

For the nine months ended September 30, 2026, SSII reported $31.4 million in revenue, versus $28.0 million for the same period in 2025. It reported a $12.0 million net loss for the 2026 nine-month period, compared with $9.7 million a year earlier.

What are the terms of SSII’s October 2026 note financing?

On October 9, 2026, SSII received $20.0 million in gross proceeds and issued a note with $21.025 million principal for a $20.0 million purchase price. It bears 8.75% annual interest, matures 36 months after issuance, is convertible at 95% of Market Price, and is subject to monthly investor redemptions beginning 12 months after issuance, payable in cash or shares.

What assets secure SSII’s convertible note?

The note is secured by SSII’s intellectual property and assets and the assets of SSI IP Holdings, Inc. The collateral excludes the assets and capital stock of SSI-India, the company’s Indian operating subsidiary.

Why did SSII report substantial doubt about its ability to continue as a going concern?

SSII reported a $36.9 million working-capital surplus and a $67.8 million accumulated deficit as of September 30, 2026, and a $12.0 million net loss for the nine months. It also disclosed dependence on related parties to fund operations and said existing cash and operating income were not expected to fund operations and business development through the next 12 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 55 11 0001676163 false Q3 --12-31 0001676163 2026-07-01 2026-09-30 0001676163 us-gaap:SubsequentEventMember ssii:GrowthCapitalPartnerLLCMember 2026-11-09 0001676163 us-gaap:SubsequentEventMember ssii:GrowthCapitalPartnerLLCMember us-gaap:CommonStockMember 2026-11-09 2026-11-09 0001676163 us-gaap:SubsequentEventMember us-gaap:CommonStockMember ssii:AdvisorMember 2026-11-04 2026-11-04 0001676163 us-gaap:SubsequentEventMember us-gaap:CommonStockMember ssii:OneIndividualMember ssii:ConsultingServicesAgreementMember 2026-10-20 2026-10-20 0001676163 us-gaap:SubsequentEventMember ssii:OneIndividualMember us-gaap:WarrantMember 2026-10-20 2026-10-20 0001676163 us-gaap:SubsequentEventMember us-gaap:CommonStockMember ssii:OneIndividualMember 2026-10-20 2026-10-20 0001676163 us-gaap:SubsequentEventMember srt:DirectorMember us-gaap:CommonStockMember 2026-10-20 2026-10-20 0001676163 us-gaap:SubsequentEventMember ssii:EmployeeMember us-gaap:CommonStockMember 2026-10-20 2026-10-20 0001676163 us-gaap:SubsequentEventMember us-gaap:ConvertibleCommonStockMember 2026-10-09 2026-10-09 0001676163 us-gaap:SubsequentEventMember ssii:GrowthCapitalPartnerLLCMember 2026-10-09 2026-10-09 0001676163 us-gaap:SubsequentEventMember 2026-10-09 2026-10-09 0001676163 us-gaap:ConvertibleNotesPayableMember 2026-10-09 2026-10-09 0001676163 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember us-gaap:ConvertibleCommonStockMember 2026-10-09 0001676163 2026-01-01 2026-09-30 0001676163 ssii:DisputeResolutionPanelMember 2024-08-28 2024-08-28 0001676163 ssii:DisputeResolutionPanelMember 2024-08-28 0001676163 2023-11-29 2023-11-29 0001676163 ssii:JulyTwoThousandThirtyFirstMember 2026-01-01 2026-09-30 0001676163 ssii:MarchTwoThousandThirtyMember 2026-01-01 2026-09-30 0001676163 ssii:ThirtyFirstJulyTwoThousandThirtyMember 2026-01-01 2026-09-30 0001676163 ssii:ThirtyFirstMayTwoThousandThirtyTwoMember 2026-01-01 2026-09-30 0001676163 ssii:MarchTwoThousandTwentyOneMember 2026-01-01 2026-09-30 0001676163 2026-09-30 0001676163 ssii:VishwajyotiPSrivastavaMDMember 2025-12-31 0001676163 ssii:SushrutaPrivateLimitedOneMember 2025-12-31 0001676163 ssii:SushrutaPrivateLimitedOneMember 2026-09-30 0001676163 ssii:TelegnosisPrivateLimitedMember 2025-12-31 0001676163 ssii:TelegnosisPrivateLimitedMember 2026-09-30 0001676163 ssii:SudhirSrivastavaMedicalInnovationsPvtLtdMember 2025-12-31 0001676163 ssii:SudhirSrivastavaMedicalInnovationsPvtLtdMember 2026-09-30 0001676163 ssii:SudhirPremSrivastavaMDMember 2025-12-31 0001676163 ssii:SudhirPremSrivastavaMDMember 2026-09-30 0001676163 ssii:SSIPTESingaporeMember 2025-12-31 0001676163 ssii:SSIPTESingaporeMember 2026-09-30 0001676163 ssii:CardioBahamasMember 2025-12-31 0001676163 ssii:CardioBahamasMember 2026-09-30 0001676163 ssii:SSInternationalCentreForRoboticsSurgeryPvtLtdMember 2025-12-31 0001676163 ssii:SriVastavaRoboticSurgeryPvtLtdMember 2025-12-31 0001676163 ssii:SriVastavaRoboticSurgeryPvtLtdMember 2026-09-30 0001676163 ssii:SarahM.RomanoMember 2026-09-30 0001676163 ssii:BarryFCohenMember 2025-12-31 0001676163 ssii:BarryFCohenMember 2026-09-30 0001676163 ssii:SushrutaPrivateLimitedOneMember 2025-01-01 2025-09-30 0001676163 ssii:DrFredericHMollMember 2026-09-30 0001676163 ssii:MrTimAdamsMember 2026-09-30 0001676163 ssii:SarahM.RomanoMember 2026-01-01 2026-09-30 0001676163 ssii:NaveenKumarAmarMember 2025-01-01 2025-09-30 0001676163 ssii:MylswamyAnnaduraiMember 2026-01-01 2026-09-30 0001676163 ssii:MrTimAdamsMember 2026-01-01 2026-09-30 0001676163 ssii:DrSPSomashekharMember 2026-01-01 2026-09-30 0001676163 ssii:DrFredericHMollMember 2026-01-01 2026-09-30 0001676163 ssii:MilanRaoMember 2026-01-01 2026-09-30 0001676163 ssii:ArvindPalaniappanMember 2025-01-01 2025-09-30 0001676163 ssii:Dr.VishwajyotiMember 2025-01-01 2025-09-30 0001676163 ssii:Dr.VishwajyotiMember 2026-01-01 2026-09-30 0001676163 ssii:SudhirPremSrivastavaMDMember 2025-01-01 2025-09-30 0001676163 ssii:SudhirPremSrivastavaMDMember 2026-01-01 2026-09-30 0001676163 ssii:BarryFCohenMember 2025-01-01 2025-09-30 0001676163 ssii:BarryFCohenMember 2026-01-01 2026-09-30 0001676163 ssii:AnupSethiMember 2025-01-01 2025-09-30 0001676163 ssii:DrManjiriSomashekharMember 2026-01-01 2026-09-30 0001676163 ssii:VishwajyotiPSrivastavaMDMember 2025-01-01 2025-09-30 0001676163 ssii:VishwajyotiPSrivastavaMDMember 2026-01-01 2026-09-30 0001676163 ssii:DrSPSomashekharMember 2025-01-01 2025-09-30 0001676163 ssii:DrFredericHMollMember 2025-01-01 2025-09-30 0001676163 ssii:TelegnosisPvtLtdMember 2025-01-01 2025-09-30 0001676163 ssii:TelegnosisPvtLtdMember 2026-01-01 2026-09-30 0001676163 ssii:SudhirSrivastavaMedicalInnovationsPvtLtdMember 2025-01-01 2025-09-30 0001676163 ssii:SudhirSrivastavaMedicalInnovationsPvtLtdMember 2026-01-01 2026-09-30 0001676163 ssii:SSInternationalCentreForRoboticsSurgeryPvtLtdMember 2025-01-01 2025-09-30 0001676163 ssii:SriVastavaRoboticSurgeryPvtLtdMember 2025-01-01 2025-09-30 0001676163 ssii:SriVastavaRoboticSurgeryPvtLtdMember 2026-01-01 2026-09-30 0001676163 ssii:StockOptionsToEmployeesMember 2026-01-01 2026-09-30 0001676163 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001676163 ssii:UnvestedStockOptionsMember 2026-09-30 0001676163 us-gaap:RestrictedStockMember ssii:November272023Member 2026-01-01 2026-09-30 0001676163 us-gaap:StockOptionMember ssii:November272023Member 2026-01-01 2026-09-30 0001676163 us-gaap:StockOptionMember ssii:February132024Member 2026-01-01 2026-09-30 0001676163 us-gaap:RestrictedStockMember ssii:JanuaryNineTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001676163 us-gaap:RestrictedStockMember ssii:November272023Member 2026-09-30 0001676163 us-gaap:StockOptionMember ssii:November272023Member 2026-09-30 0001676163 us-gaap:StockOptionMember ssii:February132024Member 2026-09-30 0001676163 us-gaap:RestrictedStockMember ssii:JanuaryNineTwoThousandTwentySixMember 2026-09-30 0001676163 2025-01-01 2025-09-30 0001676163 ssii:AdvisoryShareMember 2025-01-01 2025-09-30 0001676163 ssii:AdvisoryShareMember 2026-01-01 2026-09-30 0001676163 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-30 0001676163 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001676163 us-gaap:StockOptionMember 2025-01-01 2025-09-30 0001676163 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0001676163 ssii:StockOptionsRSUAndAdvisorySharesMember 2025-01-01 2025-09-30 0001676163 ssii:StockOptionsRSUAndAdvisorySharesMember 2026-01-01 2026-09-30 0001676163 2025-01-01 2025-12-31 0001676163 ssii:AdvisoryShareMember 2026-09-30 0001676163 ssii:AdvisoryShareMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:TenAugustTwoThousandTwentySixMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:TenAugustTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:FourAugustTwoThousandTwentySixMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:FourAugustTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:TwentyThirdJulyTwoThousandTwentySixMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:TwentyThirdJulyTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:SixteenJulyTwoThousandTwentySixOneMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:SixteenJulyTwoThousandTwentySixOneMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:SixteenJulyTwoThousandTwentySixMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:SixteenJulyTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThreeJulyTwoThousandTwentySixOneMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThreeJulyTwoThousandTwentySixMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:TwoJulyTwoThousandTwentyMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeFourMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeFourMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeFourMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeThreeMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeThreeMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeThreeMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeTwoMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeTwoMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeTwoMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeOneMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeOneMember 2026-01-01 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThirtyFirstOctoberTwoThousandTwentyThreeOneMember 2025-12-31 0001676163 ssii:RestrictedStockAwardsMember 2026-01-01 2026-09-30 0001676163 us-gaap:RestrictedStockMember 2026-09-30 0001676163 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0001676163 us-gaap:RestrictedStockMember 2025-12-31 0001676163 2025-12-31 0001676163 ssii:TwoThousandAndSixteenIncentiveStockPlanMember ssii:RestrictedStockAwardEmployeesMember ssii:RestrictedStockAwardsVestMember 2026-01-01 2026-09-30 0001676163 ssii:TwoThousandAndSixteenIncentiveStockPlanMember ssii:RestrictedStockAwardEmployeesMember 2026-09-30 0001676163 ssii:TwoThousandAndSixteenIncentiveStockPlanMember ssii:StockOptionsToEmployeesMember 2026-01-01 2026-09-30 0001676163 ssii:TwoThousandAndSixteenIncentiveStockPlanMember ssii:StockOptionsToEmployeesMember ssii:RestrictedStockAwardsVestMember 2026-01-01 2026-09-30 0001676163 ssii:TwoThousandAndSixteenIncentiveStockPlanMember ssii:StockOptionsToEmployeesMember 2026-09-30 0001676163 ssii:SecurityDepositMember 2026-09-30 0001676163 us-gaap:FairValueInputsLevel3Member ssii:FairValueMember 2025-12-31 0001676163 us-gaap:FairValueInputsLevel3Member ssii:FairValueMember 2026-09-30 0001676163 us-gaap:FairValueInputsLevel3Member ssii:CarryingValueMember 2025-12-31 0001676163 us-gaap:FairValueInputsLevel3Member ssii:CarryingValueMember 2026-09-30 0001676163 2025-06-30 0001676163 2024-12-31 0001676163 2025-07-01 2025-09-30 0001676163 us-gaap:RetirementPlanNameOtherMember 2025-01-01 2025-09-30 0001676163 us-gaap:RetirementPlanNameOtherMember 2026-01-01 2026-09-30 0001676163 us-gaap:RetirementPlanNameOtherMember 2025-07-01 2025-09-30 0001676163 us-gaap:RetirementPlanNameOtherMember 2026-07-01 2026-09-30 0001676163 ssii:VillageChhatarpur18491852FarmMember 2025-12-31 0001676163 ssii:VillageChhatarpur18491852FarmMember 2026-09-30 0001676163 ssii:IlabsInfoTechnology7thFloorMember 2026-09-30 0001676163 ssii:IlabsInfoTechnologyBasement3Member 2025-12-31 0001676163 ssii:IlabsInfoTechnologyBasement3Member 2026-09-30 0001676163 ssii:IlabsInfoTechnologyGroundFloorMember 2025-12-31 0001676163 ssii:IlabsInfoTechnologyGroundFloorMember 2026-09-30 0001676163 ssii:IlabsInfoTechnology1stFloorMember 2025-12-31 0001676163 ssii:IlabsInfoTechnology1stFloorMember 2026-09-30 0001676163 ssii:IlabsInfoTechnoogy3rdFloorMember 2025-12-31 0001676163 ssii:IlabsInfoTechnoogy3rdFloorMember 2026-09-30 0001676163 2025-09-30 0001676163 2026-06-30 0001676163 ssii:SystemMember 2026-09-30 0001676163 us-gaap:CommonStockMember 2026-09-14 2026-09-14 0001676163 us-gaap:CommonStockMember 2026-09-14 0001676163 us-gaap:CommonStockMember 2026-08-19 2026-08-19 0001676163 us-gaap:CommonStockMember 2026-08-19 0001676163 us-gaap:CommonStockMember ssii:AdvisoryServicesAgreement.Member 2026-08-19 2026-08-19 0001676163 ssii:ConsultingAgreementMember 2026-08-10 2026-08-10 0001676163 us-gaap:CommonStockMember 2026-07-03 2026-07-03 0001676163 us-gaap:CommonStockMember 2026-07-03 0001676163 us-gaap:CommonStockMember 2026-06-20 2026-06-20 0001676163 ssii:NewInvestorsMember 2026-03-06 2026-03-06 0001676163 ssii:NewInvestorsMember 2026-03-06 0001676163 ssii:TimAdamsMember 2026-03-06 2026-03-06 0001676163 ssii:TimAdamsMember 2026-03-06 0001676163 ssii:DrSudhirSrivastavaMember 2026-03-06 2026-03-06 0001676163 ssii:DrFredericMollMember 2026-03-06 0001676163 ssii:DrSudhirSrivastavaMember 2026-03-06 0001676163 ssii:DirectorsMember 2026-03-06 2026-03-06 0001676163 ssii:DirectorsMember 2026-03-06 0001676163 ssii:NonaffiliateMember us-gaap:CommonStockMember 2026-03-06 0001676163 ssii:TwoThousandAndSixteenIncentiveStockPlanMember 2026-01-09 0001676163 us-gaap:WarrantMember 2025-12-12 2025-12-12 0001676163 us-gaap:CommonStockMember 2025-12-12 0001676163 ssii:OneIndividualMember 2025-12-12 0001676163 us-gaap:CommonStockMember 2025-11-27 2025-11-27 0001676163 ssii:CommonStockIssuedPostMergerMember us-gaap:CommonStockMember 2025-10-22 2025-10-22 0001676163 us-gaap:CommonStockMember 2025-10-22 2025-10-22 0001676163 us-gaap:CommonStockMember 2025-10-01 2025-10-01 0001676163 ssii:CommonStockIssuedPostMergerMember us-gaap:CommonStockMember 2025-08-28 2025-08-28 0001676163 us-gaap:CommonStockMember 2025-08-28 0001676163 us-gaap:CommonStockMember 2025-08-28 2025-08-28 0001676163 us-gaap:CommonStockMember 2025-05-28 2025-05-28 0001676163 ssii:CommonStockIssuedPostMergerMember us-gaap:CommonStockMember 2025-05-22 2025-05-22 0001676163 2025-05-22 0001676163 us-gaap:CommonStockMember 2025-05-22 2025-05-22 0001676163 us-gaap:CommonStockMember 2025-04-30 2025-04-30 0001676163 us-gaap:CommonStockMember 2025-04-02 2025-04-02 0001676163 us-gaap:CommonStockMember 2025-03-31 2025-03-31 0001676163 us-gaap:CommonStockMember 2025-03-01 2025-03-01 0001676163 2025-03-01 2025-03-01 0001676163 us-gaap:CommonStockMember 2025-02-20 2025-02-20 0001676163 us-gaap:CommonStockMember ssii:SushrutaPvtLtdMember 2025-02-20 2025-02-20 0001676163 2025-02-13 2025-02-13 0001676163 us-gaap:CommonStockMember 2025-02-13 2025-02-13 0001676163 ssii:CommonStockIssuedPostMergerMember 2025-02-13 2025-02-13 0001676163 ssii:CommonStockIssuedPostMergerMember us-gaap:CommonStockMember 2025-02-13 2025-02-13 0001676163 2025-02-12 2025-02-12 0001676163 us-gaap:CommonStockMember 2025-02-12 2025-02-12 0001676163 ssii:DrFredericMollMember us-gaap:CommonStockMember 2023-04-14 2023-04-14 0001676163 2023-04-14 2023-04-14 0001676163 us-gaap:SeriesAPreferredStockMember ssii:CardioVenturesMember 2023-04-14 0001676163 us-gaap:SeriesAPreferredStockMember ssii:CardioVenturesMember 2023-04-14 2023-04-14 0001676163 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001676163 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001676163 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001676163 us-gaap:PreferredStockMember 2026-09-30 0001676163 country:NP 2025-01-01 2025-09-30 0001676163 country:NP 2026-01-01 2026-09-30 0001676163 country:AE 2025-01-01 2025-09-30 0001676163 country:AE 2026-01-01 2026-09-30 0001676163 country:IQ 2025-01-01 2025-09-30 0001676163 country:ID 2025-01-01 2025-09-30 0001676163 country:ID 2026-01-01 2026-09-30 0001676163 country:PH 2025-01-01 2025-09-30 0001676163 country:PH 2026-01-01 2026-09-30 0001676163 ssii:SriLanka1Member 2026-01-01 2026-09-30 0001676163 srt:SouthAmericaMember 2025-01-01 2025-09-30 0001676163 srt:SouthAmericaMember 2026-01-01 2026-09-30 0001676163 country:IN 2025-01-01 2025-09-30 0001676163 country:IN 2026-01-01 2026-09-30 0001676163 ssii:TrainingIncomeMember 2026-01-01 2026-09-30 0001676163 ssii:LeaseIncomeMember 2025-01-01 2025-09-30 0001676163 ssii:LeaseIncomeMember 2026-01-01 2026-09-30 0001676163 ssii:WarrantySaleMember 2025-01-01 2025-09-30 0001676163 ssii:WarrantySaleMember 2026-01-01 2026-09-30 0001676163 ssii:InstrumentsSaleMember 2025-01-01 2025-09-30 0001676163 ssii:InstrumentsSaleMember 2026-01-01 2026-09-30 0001676163 ssii:SystemSalesMember 2025-01-01 2025-09-30 0001676163 ssii:SystemSalesMember 2026-01-01 2026-09-30 0001676163 country:IQ 2025-07-01 2025-09-30 0001676163 country:ID 2025-07-01 2025-09-30 0001676163 country:NP 2025-07-01 2025-09-30 0001676163 country:NP 2026-07-01 2026-09-30 0001676163 country:AE 2025-07-01 2025-09-30 0001676163 country:AE 2026-07-01 2026-09-30 0001676163 country:PH 2026-07-01 2026-09-30 0001676163 ssii:SriLanka1Member 2026-07-01 2026-09-30 0001676163 srt:SouthAmericaMember 2026-07-01 2026-09-30 0001676163 country:IN 2025-07-01 2025-09-30 0001676163 country:IN 2026-07-01 2026-09-30 0001676163 ssii:LeaseIncomeMember 2025-07-01 2025-09-30 0001676163 ssii:LeaseIncomeMember 2026-07-01 2026-09-30 0001676163 ssii:WarrantySaleMember 2025-07-01 2025-09-30 0001676163 ssii:WarrantySaleMember 2026-07-01 2026-09-30 0001676163 ssii:InstrumentsSaleMember 2025-07-01 2025-09-30 0001676163 ssii:InstrumentsSaleMember 2026-07-01 2026-09-30 0001676163 ssii:SystemSalesMember 2025-07-01 2025-09-30 0001676163 ssii:SystemSalesMember 2026-07-01 2026-09-30 0001676163 us-gaap:TransferredOverTimeMember 2025-12-31 0001676163 us-gaap:TransferredOverTimeMember 2026-09-30 0001676163 us-gaap:TransferredAtPointInTimeMember 2025-12-31 0001676163 us-gaap:TransferredAtPointInTimeMember 2026-09-30 0001676163 2026-07-24 2026-07-24 0001676163 ssii:TermLoanMember 2026-07-24 2026-07-24 0001676163 ssii:ICICIBankMember 2026-01-01 2026-09-30 0001676163 ssii:ICICIBankMember 2026-09-30 0001676163 ssii:HDFCBankOverdraftMember 2025-10-31 0001676163 ssii:HDFCBankMember 2025-10-31 0001676163 ssii:OverdraftFacilityMember 2026-01-01 2026-09-30 0001676163 ssii:HDFCBankLtdWCDLTwoMember 2026-09-30 0001676163 ssii:RepoRateMember 2026-01-01 2026-09-30 0001676163 ssii:HDFCBankMember 2026-01-01 2026-09-30 0001676163 ssii:HDFCBankOverdraftMember 2026-09-30 0001676163 ssii:HDFCBankMember 2026-09-30 0001676163 ssii:ECLGHSWorkingCapitalTermLoanMember 2026-09-30 0001676163 ssii:HDFCBankLtdWCDLThreeMember 2026-09-30 0001676163 ssii:HDFCBankLtdWCDLTwoMember 2025-12-31 0001676163 ssii:HDFCBankLtdWCDLOneMember 2026-09-30 0001676163 ssii:HDFCBankLtdOverdraftTwoMember 2025-12-31 0001676163 ssii:HDFCBankLtdOverdraftTwoMember 2026-09-30 0001676163 ssii:HDFCBankLtdOverdraftOneMember 2025-12-31 0001676163 ssii:HDFCBankLtdOverdraftOneMember 2026-09-30 0001676163 ssii:ConvertiblePromissoryNoteMember ssii:SushrutaPvtLtdMember 2025-03-31 0001676163 ssii:SushrutaPvtLtdMember 2025-03-01 2025-03-31 0001676163 ssii:ConvertibleNotesMember ssii:SushrutaPvtLtdMember 2025-02-01 2025-02-28 0001676163 ssii:OneYearConvertiblePromissoryNotesMember 2025-02-01 2025-02-28 0001676163 ssii:ConvertiblePromissoryNoteMember 2025-02-01 2025-02-28 0001676163 ssii:PromissoryNotesMember ssii:SushrutaPvtLtdMember 2025-02-01 2025-02-28 0001676163 ssii:PromissoryNotesMember 2025-02-01 2025-02-28 0001676163 ssii:OneYearNotesMember 2025-01-31 0001676163 ssii:ConvertiblePromissoryNoteMember 2025-01-01 2025-01-31 0001676163 ssii:AffiliateMember 2025-01-01 2025-01-31 0001676163 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2025-12-31 0001676163 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2026-09-30 0001676163 ssii:LienAgainstCreditCardFacilityMember 2026-09-30 0001676163 ssii:LienAgainstBankGuaranteeMember 2025-12-31 0001676163 ssii:LienAgainstBankGuaranteeMember 2026-09-30 0001676163 ssii:LienAgainstCreditCardFacilityMember 2025-12-31 0001676163 ssii:LienAgainstOverdraftFacilityMember 2025-12-31 0001676163 ssii:LienAgainstOverdraftFacilityMember 2026-09-30 0001676163 us-gaap:CustomerConcentrationRiskMember ssii:CustomerAMember us-gaap:AccountsReceivableMember 2026-01-01 2026-09-30 0001676163 us-gaap:CustomerConcentrationRiskMember ssii:CustomerAMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001676163 us-gaap:CustomerConcentrationRiskMember ssii:CustomerAMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001676163 ssii:CapitalWorkInProgressMember 2026-09-30 0001676163 ssii:DemoSystemMember 2025-12-31 0001676163 ssii:DemoSystemMember 2026-09-30 0001676163 us-gaap:VehiclesMember 2025-12-31 0001676163 us-gaap:VehiclesMember 2026-09-30 0001676163 ssii:ServerNetworkingMember 2025-12-31 0001676163 ssii:ServerNetworkingMember 2026-09-30 0001676163 us-gaap:MachineryAndEquipmentMember 2025-12-31 0001676163 us-gaap:MachineryAndEquipmentMember 2026-09-30 0001676163 ssii:PayPerUseSystemsMember 2025-12-31 0001676163 ssii:PayPerUseSystemsMember 2026-09-30 0001676163 us-gaap:OfficeEquipmentMember 2025-12-31 0001676163 us-gaap:OfficeEquipmentMember 2026-09-30 0001676163 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001676163 us-gaap:LeaseholdImprovementsMember 2026-09-30 0001676163 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001676163 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001676163 us-gaap:ComputerEquipmentMember 2025-12-31 0001676163 us-gaap:ComputerEquipmentMember 2026-09-30 0001676163 ssii:ServerAndNetworkingMember srt:MaximumMember 2026-09-30 0001676163 ssii:ServerAndNetworkingMember srt:MinimumMember 2026-09-30 0001676163 ssii:PlantAndMachineryMember 2026-09-30 0001676163 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2026-09-30 0001676163 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2026-09-30 0001676163 srt:MaximumMember 2026-09-30 0001676163 srt:MinimumMember 2026-09-30 0001676163 srt:MaximumMember 2026-01-01 2026-09-30 0001676163 srt:MinimumMember 2026-01-01 2026-09-30 0001676163 currency:USD ssii:AverageRateTranslationMember 2025-12-31 0001676163 currency:USD ssii:ClosingRateTranslationMember 2025-12-31 0001676163 currency:USD ssii:AverageRateTranslationMember 2025-09-30 0001676163 currency:USD ssii:ClosingRateTranslationMember 2025-09-30 0001676163 currency:USD ssii:AverageRateTranslationMember 2026-09-30 0001676163 currency:USD ssii:ClosingRateTranslationMember 2026-09-30 0001676163 us-gaap:SubsequentEventMember ssii:GrowthCapitalPartnerLLCMember 2026-10-09 2026-10-09 0001676163 ssii:ManipalGlobalHealthServicesMember 2026-01-01 2026-09-30 0001676163 us-gaap:CommonStockMember 2026-09-30 0001676163 ssii:TimAdamsDirectorMember 2026-01-01 2026-09-30 0001676163 ssii:TimAdamsDirectorMember 2026-09-30 0001676163 ssii:DrFredericMollViceChairmanMember 2026-01-01 2026-09-30 0001676163 ssii:DrFredericMollViceChairmanMember 2026-09-30 0001676163 ssii:ChairmanMember 2026-01-01 2026-09-30 0001676163 ssii:ChairmanMember 2026-09-30 0001676163 ssii:DirectorsAndExecutiveOfficersMember 2026-01-01 2026-09-30 0001676163 ssii:DirectorsAndExecutiveOfficersMember 2026-09-30 0001676163 us-gaap:CommonStockMember 2026-03-06 2026-03-06 0001676163 ssii:SSInternationalCentreForRoboticsSurgeryPrivateLimitedMember 2026-01-01 2026-09-30 0001676163 us-gaap:SeriesAPreferredStockMember us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2026-09-30 0001676163 ssii:SSInternationalCentreForRoboticsSurgeryPrivateLimitedMember 2026-09-30 0001676163 us-gaap:RetainedEarningsMember 2025-09-30 0001676163 ssii:CapitalReserveMember 2025-09-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001676163 us-gaap:CommonStockMember 2025-09-30 0001676163 us-gaap:PreferredStockMember 2025-09-30 0001676163 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001676163 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001676163 us-gaap:RetainedEarningsMember 2025-06-30 0001676163 ssii:CapitalReserveMember 2025-06-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001676163 us-gaap:CommonStockMember 2025-06-30 0001676163 us-gaap:PreferredStockMember 2025-06-30 0001676163 2025-04-01 2025-06-30 0001676163 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001676163 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001676163 2025-03-31 0001676163 us-gaap:RetainedEarningsMember 2025-03-31 0001676163 ssii:CapitalReserveMember 2025-03-31 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001676163 us-gaap:CommonStockMember 2025-03-31 0001676163 us-gaap:PreferredStockMember 2025-03-31 0001676163 2025-01-01 2025-03-31 0001676163 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001676163 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001676163 us-gaap:RetainedEarningsMember 2024-12-31 0001676163 ssii:CapitalReserveMember 2024-12-31 0001676163 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001676163 us-gaap:CommonStockMember 2024-12-31 0001676163 us-gaap:PreferredStockMember 2024-12-31 0001676163 us-gaap:RetainedEarningsMember 2026-09-30 0001676163 ssii:CapitalReserveMember 2026-09-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001676163 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001676163 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001676163 us-gaap:RetainedEarningsMember 2026-06-30 0001676163 ssii:CapitalReserveMember 2026-06-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001676163 us-gaap:CommonStockMember 2026-06-30 0001676163 us-gaap:PreferredStockMember 2026-06-30 0001676163 2026-04-01 2026-06-30 0001676163 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001676163 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001676163 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001676163 2026-03-31 0001676163 us-gaap:RetainedEarningsMember 2026-03-31 0001676163 ssii:CapitalReserveMember 2026-03-31 0001676163 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001676163 us-gaap:CommonStockMember 2026-03-31 0001676163 us-gaap:PreferredStockMember 2026-03-31 0001676163 2026-01-01 2026-03-31 0001676163 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001676163 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001676163 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001676163 us-gaap:RetainedEarningsMember 2025-12-31 0001676163 ssii:CapitalReserveMember 2025-12-31 0001676163 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001676163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001676163 us-gaap:CommonStockMember 2025-12-31 0001676163 us-gaap:PreferredStockMember 2025-12-31 0001676163 ssii:SeriesANonConvertiblePreferredStockMember 2025-12-31 0001676163 ssii:SeriesANonConvertiblePreferredStockMember 2026-09-30 0001676163 2026-11-13 0001676163 us-gaap:CustomerConcentrationRiskMember ssii:CustomerAMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001676163 us-gaap:CustomerConcentrationRiskMember ssii:CustomerAMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001676163 us-gaap:CustomerConcentrationRiskMember ssii:CustomerAMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31 0001676163 ssii:ECLGHSWorkingCapitalTermLoanMember 2025-12-31 0001676163 ssii:HDFCBankLtdWCDLThreeMember 2025-12-31 0001676163 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001676163 ssii:SSInternationalCentreForRoboticsSurgeryPvtLtdMember 2026-01-01 2026-09-30 0001676163 ssii:TrainingIncomeMember 2025-01-01 2025-09-30 0001676163 ssii:CapitalReserveMember 2025-04-01 2025-06-30 0001676163 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001676163 ssii:CapitalReserveMember 2026-04-01 2026-06-30 0001676163 country:IQ 2026-07-01 2026-09-30 0001676163 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001676163 ssii:CapitalReserveMember 2026-01-01 2026-03-31 0001676163 ssii:CapitalReserveMember 2025-01-01 2025-03-31 0001676163 ssii:MilanRaoMember 2025-01-01 2025-09-30 0001676163 ssii:MrTimAdamsMember 2025-01-01 2025-09-30 0001676163 country:PH 2025-07-01 2025-09-30 0001676163 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001676163 country:IQ 2026-01-01 2026-09-30 0001676163 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001676163 ssii:AnupSethiMember 2026-01-01 2026-09-30 0001676163 ssii:SushrutaPrivateLimitedOneMember 2026-01-01 2026-09-30 0001676163 ssii:MrTimAdamsMember 2025-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThreeJulyTwoThousandTwentySixOneMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:SixteenJulyTwoThousandTwentySixMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:SixteenJulyTwoThousandTwentySixOneMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:TwentyThirdJulyTwoThousandTwentySixMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:TwoJulyTwoThousandTwentyMember 2026-09-30 0001676163 ssii:SushrutaPrivateLimitedOneMember 2025-09-30 0001676163 ssii:VishwajyotiPSrivastavaMDMember 2026-09-30 0001676163 country:ID 2026-07-01 2026-09-30 0001676163 ssii:CapitalReserveMember 2026-07-01 2026-09-30 0001676163 ssii:CapitalReserveMember 2025-07-01 2025-09-30 0001676163 ssii:DrManjiriSomashekharMember 2025-01-01 2025-09-30 0001676163 ssii:NaveenKumarAmarMember 2026-01-01 2026-09-30 0001676163 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001676163 ssii:MylswamyAnnaduraiMember 2025-01-01 2025-09-30 0001676163 ssii:AdvisoryShareMember ssii:TwoJulyTwoThousandTwentyMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:ThreeJulyTwoThousandTwentySixMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:FourAugustTwoThousandTwentySixMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:TenAugustTwoThousandTwentySixMember 2025-12-31 0001676163 ssii:AdvisoryShareMember ssii:ThreeJulyTwoThousandTwentySixMember 2026-09-30 0001676163 ssii:AdvisoryShareMember ssii:ThreeJulyTwoThousandTwentySixOneMember 2026-09-30 0001676163 ssii:IlabsInfoTechnology7thFloorMember 2025-12-31 0001676163 ssii:SystemMember 2025-12-31 0001676163 us-gaap:DomesticCountryMember 2025-07-01 2025-09-30 0001676163 us-gaap:DomesticCountryMember 2026-01-01 2026-09-30 0001676163 us-gaap:DomesticCountryMember 2025-01-01 2025-09-30 0001676163 us-gaap:StateAndLocalJurisdictionMember 2025-01-01 2025-09-30 0001676163 ssii:SriLanka1Member 2025-01-01 2025-09-30 0001676163 ssii:CapitalWorkInProgressMember 2025-12-31 0001676163 ssii:SriLanka1Member 2025-07-01 2025-09-30 0001676163 ssii:SarahM.RomanoMember 2025-01-01 2025-09-30 0001676163 ssii:SarahM.RomanoMember 2025-12-31 0001676163 us-gaap:StateAndLocalJurisdictionMember 2026-07-01 2026-09-30 0001676163 us-gaap:StateAndLocalJurisdictionMember 2025-07-01 2025-09-30 0001676163 us-gaap:DomesticCountryMember 2026-07-01 2026-09-30 0001676163 us-gaap:StateAndLocalJurisdictionMember 2026-01-01 2026-09-30 0001676163 ssii:HDFCBankLtdWCDLOneMember 2025-12-31 0001676163 ssii:SSInternationalCentreForRoboticsSurgeryPvtLtdMember 2026-09-30 0001676163 ssii:ArvindPalaniappanMember 2026-01-01 2026-09-30 0001676163 ssii:DrFredericHMollMember 2025-09-30 0001676163 srt:SouthAmericaMember 2025-07-01 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ssii:Integer

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 001-42615

 

SS INNOVATIONS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Florida   47-3478854
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification No.)

 

405, 3rd Floor, iLabs Info Technology Centre

Udyog Vihar, Phase III

Gurugram, Haryana 122016, India

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: +91 73375 53469

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   SSII   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐
Non-Accelerated Filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

There were 200,577,993 shares of common stock, $0.0001 par value of the Registrant issued and outstanding as of November 13, 2026.

 

 

 

 

 

 

Unless the context otherwise requires, as used in this Quarterly Report on Form 10-Q (this “Quarterly Report”) the terms “SSi,” “the Company,” “we,” “us,” and “our” refer to SS Innovations International, Inc., and where appropriate, our subsidiaries.

 

Forward Looking Statements

 

This Quarterly Report contains statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

 

These statements are not guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict.

 

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the Securities and Exchange Commission (the “SEC”), we do not assume any obligation to update any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

 

 

 

 

TABLE OF CONTENTS

 

      Page
       
PART I – FINANCIAL INFORMATION   1
       
Item 1. Financial Statements   1
       
  Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025   1
       
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and September 30, 2025 (unaudited)   2
       
  Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and September 30, 2025 (unaudited)   4
       
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and September 30, 2025 (unaudited)   5
       
  Notes to Condensed Consolidated Financial Statements (unaudited)   6
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   40
       
Item 3. Quantitative and Qualitative Disclosures About Market Risk   46
       
Item 4. Controls and Procedures   46
       
PART II – OTHER INFORMATION   48
       
Item 1. Legal Proceedings   48
       
Item 1A.  Risk Factors   48
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   48
       
Item 3. Defaults Upon Senior Securities   48
       
Item 4. Mine Safety Disclosures   48
       
Item 5. Other Information   48
       
Item 6. Exhibits   48
       
SIGNATURES   49

 

i

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

          As of  
    Notes     September 30,
2026
    December 31,
2025
 
          (Unaudited)        
ASSETS                  
Current Assets:                  
Cash and cash equivalents     7     $ 8,113,767     $ 3,206,406  
Restricted cash     7       10,121,321       5,937,650  
Accounts receivable, net     6       16,764,399       12,398,542  
Inventory     14       22,071,213       17,064,002  
Prepaids and other current assets     8       13,559,139       10,166,823  
Total Current Assets             70,629,839       48,773,423  
                         
Property, plant, and equipment, net     4       9,760,506       9,100,546  
Right of use asset, net     15       2,825,720       2,754,020  
Deferred tax assets, net     16       948,965       533,727  
Accounts receivable, net-non current     6       7,314,087       8,566,654  
Restricted cash- non current     7       369,845       458,964  
Prepaids and other non current assets     8       4,658,449       4,038,883  
Total Assets           $ 96,507,411     $ 74,226,217  
                         
LIABILITIES AND STOCKHOLDERS’ EQUITY                        
Current Liabilities                        
Short-term borrowings     11     $ 16,887,869     $ 11,442,948  
Current maturities of long-term debt     11       52,136       -  
Current portion of operating lease liabilities     15       705,711       579,169  
Accounts payable     9       6,328,993       5,127,193  
Deferred revenue     12       3,720,231       3,266,686  
Accrued expenses & other current liabilities     9       6,000,556       5,825,702  
Total Current Liabilities             33,695,496       26,241,698  
                         
Operating lease liabilities, less current portion     15       2,326,354       2,337,697  
Deferred revenue- non current     12       8,720,583       7,139,807  
Long-term debt, net of current portion     11       1,199,138       -  
Other non current liabilities     9       625,229       288,764  
Total Liabilities           $ 46,566,800     $ 36,007,966  
Commitments and contingencies     21                  
Stockholders’ equity:                        
                         
Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share; 1,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025     13       1       1  
Common stock, 250,000,000 shares authorized, $0.0001 par value, 200,488,427 shares and 194,165,141 shares issued and outstanding as of September 30, 2026 and December 31, 2025 respectively     13       20,049       19,416  
Accumulated other comprehensive income (loss)     13       (4,547,638 )     (2,022,660 )
Additional paid in capital     13       121,383,836       95,111,511  
Capital reserve             899,917       899,917  
Accumulated deficit             (67,815,554 )     (55,789,934 )
Total stockholders’ equity             49,940,611       38,218,251  
Total liabilities and stockholders’ equity           $ 96,507,411     $ 74,226,217  

 

See accompanying notes to Condensed Consolidated Financial Statements

 

1

 

 

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

          For the three months ended  
    Notes     September 30,
2026
    September 30,
2025
 
                   
REVENUES                  
System sales     12       4,720,096       11,705,375  
Instruments sale     12       1,039,939       854,440  
Warranty sale     12       555,127       244,399  
Lease income     12       15,899       25,135  
Total revenue           $ 6,331,061     $ 12,829,349  
Cost of revenue             (3,223,059 )     (6,664,413 )
                         
GROSS PROFIT             3,108,002       6,164,936  
                         
OPERATING EXPENSES:                        
Research & development expense             2,500,826       786,319  
Stock compensation expense     19       2,153,984       2,095,163  
Depreciation and amortization expense     4       359,249       297,173  
Selling, general and administrative expense             4,150,363       4,821,552  
TOTAL OPERATING EXPENSES             9,164,422       8,000,207  
                         
Loss from operations             (6,056,420 )     (1,835,271 )
                         
OTHER INCOME / EXPENSE:                        
Interest Expense             (454,549 )     (176,636 )
Interest and other income, net             557,321       141,002  
TOTAL INCOME / (EXPENSE), NET             102,772       (35,634 )
                         
LOSS BEFORE INCOME TAXES             (5,953,648 )     (1,870,905 )
Income tax expense     16       (204,259 )     1,847,059  
NET LOSS           $ (5,749,389 )   $ (3,717,964 )
                         
Net loss per share - basic and diluted     2(r)   $ (0.03 )   $ (0.02 )
Weighted average- basic shares     2(r)     200,377,964       193,589,845  
Weighted average- diluted shares     2(r)     209,651,802       202,856,501  
                         
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS                        
                         
NET LOSS           $ (5,749,389 )   $ (3,717,964 )
                         
OTHER COMPREHENSIVE INCOME (LOSS)                        
Foreign currency translation loss             (561,469 )     (480,822 )
Retirement Benefit     17       6,708       (544 )
RECLASSIFICATION ADJUSTMENTS:                        
Retirement Benefit (1)             2,978       -  
Income tax effects relating to retirement benefit (1)     16       (1,688 )     (646 )
TOTAL OTHER COMPREHENSIVE LOSS             (553,471 )     (482,012 )
TOTAL COMPREHENSIVE LOSS           $ (6,302,860 )   $ (4,199,976 )

 

(1) These are reclassified to net loss and are included in other expense in the condensed consolidated statements of operations.

 

See accompanying notes to Condensed Consolidated Financial Statements.

 

2

 

 

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

          For the nine months ended  
    Notes     September 30,
2026
    September 30,
2025
 
                   
REVENUES                  
System sales     12       26,657,452       24,988,895  
Instruments sale     12       3,333,692       2,339,478  
Warranty sale     12       1,331,815       560,262  
Lease income     12       49,177       61,629  
Training income     12       41,825       -  
Total revenue           $ 31,413,961     $ 27,950,264  
Cost of revenue             (15,835,963 )     (14,783,062 )
                         
GROSS PROFIT             15,577,998       13,167,202  
                         
OPERATING EXPENSES:                        
Research & development expense             5,891,960       2,295,014  
Stock compensation expense     19       7,476,455       6,104,670  
Depreciation and amortization expense     4       1,029,360       766,416  
Selling, general and administrative expense             13,165,885       11,460,139  
TOTAL OPERATING EXPENSES             27,563,660       20,626,239  
                         
Loss from operations             (11,985,662 )     (7,459,037 )
                         
OTHER INCOME / EXPENSE:                        
Interest Expense             (1,083,361 )     (773,341 )
Interest and other income, net             1,495,772       777,158  
TOTAL INCOME / (EXPENSE), NET             412,411       3,817  
                         
LOSS BEFORE INCOME TAXES             (11,573,251 )     (7,455,220 )
Income tax expense     16       452,369       2,200,788  
NET LOSS           $ (12,025,620 )   $ (9,656,008 )
                         
Net loss per share - basic and diluted     2(r)   $ (0.06 )   $ (0.05 )
Weighted average- basic shares     2(r)     198,856,670       188,720,115  
Weighted average- diluted shares     2(r)     208,130,508       197,979,738  
                         
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS                        
                         
NET LOSS           $ (12,025,620 )   $ (9,656,008 )
                         
OTHER COMPREHENSIVE INCOME (LOSS)                        
Foreign currency translation loss             (2,523,447 )     (539,960 )
Retirement Benefit     17       (14,162 )     (20,366 )
RECLASSIFICATION ADJUSTMENTS:                        
Retirement Benefit (1)             9,067       -  
Income tax effects relating to retirement benefit (1)     16       3,564       5,126  
TOTAL OTHER COMPREHENSIVE LOSS             (2,524,978 )     (555,200 )
TOTAL COMPREHENSIVE LOSS           $ (14,550,598 )   $ (10,211,208 )

 

(1) These are reclassified to net loss and are included in other expense in the condensed consolidated statements of operations.

 

See accompanying notes to Condensed Consolidated Financial Statements.

 

3

 

 

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND SEPTEMBER 30, 2025

(Unaudited)

 

        Preferred Stock     Common Stock     Accumulated
other
comprehensive
    Additional
Paid-In
    Capital     Accumulated     Total
Stockholders’
 
    Notes   Number     Amount     Number     Amount     income (loss)     Capital     Reserve     Deficit     equity  
                                                           
Balance as at December 31, 2025         1,000       1       194,165,141       19,416       (2,022,660 )     95,111,511       899,917       (55,789,934 )            38,218,251  
Proceeds from Private investment in Public Equity, net of issuance costs   13     -       -       5,774,839       578       -       18,445,920       -       -       18,446,498  
Stock compensation   19     -       -       -       -       -       1,934,303       -       -       1,934,303  
Stock grants   13     -       -       191,555       19       -       1,057,390       -       -       1,057,409  
Net loss         -       -       -       -       (1,550,477 )     -       -       (3,582,571 )     (5,133,048 )
                                                                             
Balance as at March 31, 2026         1,000       1       200,131,535       20,013       (3,573,137 )     116,549,124       899,917       (59,372,505 )     54,523,413  
                                                                             
Stock compensation   19     -       -       -       -       -       1,790,039       -       -       1,790,039  
Stock issued for services   13     -       -       37,500       4       -       170,146       -       -       170,150  
Net loss         -       -       -       -       (421,029 )     -       -       (2,693,660 )     (3,114,689 )
                                                                             
Balance as at June 30, 2026         1,000       1       200,169,035       20,017       (3,994,166 )     118,509,309       899,917       (62,066,165 )     53,368,913  
                                                                             
Stock compensation   19     -       -       -       -       -       1,716,193       -       -       1,716,193  
Stock issued for services   13     -       -       319,392       32       -       1,158,333       -       -       1,158,365  
Net loss         -       -       -       -       (553,471 )     -       -       (5,749,389 )     (6,302,860 )
                                                                             
Balance as at September 30, 2026         1,000       1       200,488,427       20,049       (4,547,638 )     121,383,836       899,917       (67,815,554 )     49,940,611  
                                                                             
Balance as at December 31, 2024         1,000       1       171,579,284       17,157       (749,625 )     56,952,200       899,917       (43,662,547 )     13,457,103  
                                                                             
Stock compensation   19     -       -       -       -       -       2,110,467       -       -       2,110,467  
Common stock issued against exercise of warrants   13     -       -       10,477       1       -       (1 )     -       -       -  
Conversion of notes payable to equity   10     -       -       21,966,416       2,196       -       30,643,163       -       -       30,645,359  
Net loss         -       -       -       -       22,714       -       -       (5,681,353 )     (5,658,639 )
                                                                             
Balance as at March 31, 2025         1,000       1       193,556,177       19,354       (726,911 )     89,705,829       899,917       (49,343,900 )     40,554,290  
                                                                             
Stock compensation   19     -       -       -       -       -       1,579,376       -       -       1,579,376  
Common stock issued against exercise of options   13     -       -       7,431       1       -       (1 )     -       -       -  
Stock issued for services   10     -       -       24,802       2       -       241,795       -       -       241,797  
Net loss         -       -       -       -       (95,902 )             -       (256,691 )     (352,593 )
                                                                             
Balance as at June 30, 2025         1,000       1       193,588,410       19,357       (822,813 )     91,526,999       899,917       (49,600,591 )     42,022,870  
                                                                             
Stock compensation                                                 1,782,853                       1,782,853  
Common stock issued against exercise of options                                                                         -  
Stock issued for services                         4,000       0               43,560                       43,560  
Net loss                                         (482,012 )                     (3,717,964 )     (4,199,976 )
                                                                             
Balance as at September 30, 2025         1,000       1       193,592,410       19,358       (1,304,825 )     93,353,412       899,917       (53,318,555 )     39,649,306  

 

4

 

 

SS INNOVATIONS INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

    For the nine months ended  
    September 30,
2026
    September 30,
2025
 
Cash flows from operating activities:            
             
Net loss   $ (12,025,620 )   $ (9,656,008 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     1,029,360       766,416  
Operating lease expense     733,038       600,006  
Interest expense     201,290       175,243  
Interest and other income, net     (1,020,855 )     (301,240 )
Deferred income tax benefit     (463,052 )     (155,056 )
Stock compensation expense     7,773,688       6,104,670  
Provision for credit loss reserve, net     518,575       241,403  
Provision for slow moving inventory     (6,179 )     -  
                 
Changes in operating assets and liabilities:                
Accounts receivable, net     (2,795,539 )     (6,086,871 )
Inventory, net     (5,001,032 )     (11,514,766 )
Deferred revenue     2,034,321       2,338,094  
Prepaids and other assets     (4,832,026 )     (3,450,327 )
Accounts payable     1,223,202       2,344,584  
Income taxes payable, net     (466,095 )     2,192,881  
Accrued expenses & other liabilities     859,278       (49,083 )
Operating lease payment     (677,535 )     (573,363 )
Net cash used in operating activities     (12,915,181 )     (17,023,417 )
                 
Cash flows from investing activities:                
Purchase of property, plant and equipment     (1,701,323 )     (1,944,527 )
Net cash used in investing activities     (1,701,323 )     (1,944,527 )
                 
Cash flows from financing activities:                
Proceeds from short-term borrowings (net)     5,444,921       2,074,877  
Proceeds from Private Investment in Public Equity, net of transaction costs     18,446,498       -  
Proceeds from debt (net)     1,251,274       -  
Proceeds from issuance of convertible notes to principal shareholder     -       28,000,000  
Repayment of convertible notes to principal shareholder, including interest     -       (4,212,637 )
Repayment of convertible notes to other investors, including interest     -       (1,068,849 )
Net cash provided by financing activities     25,142,693       24,793,391  
                 
Net change in cash     10,526,189       5,825,447  
Effect of exchange rate on cash     (1,524,276 )     (409,735 )
Cash and cash equivalents at the beginning of the period     9,603,020       6,623,535  
Cash and cash equivalents at end of the period   $ 18,604,933     $ 12,039,247  
                 
^ For cash and cash equivalents and restricted cash, refer Note 7                
                 
Supplemental disclosure of cash flow information:                
Transaction costs relating to Private Investment in Public Equity   $ 175,000     $ -  
Conversion of accrued liabilities into common stock   $ 276,567     $ -  
Conversion of common stock into prepaid expense   $ 675,100     $ -  
Conversion of convertible notes into common stock, including interest   $ -     $ 30,645,360  
Transfer of systems from inventory to property, plant and equipment   $ -     $ 2,167,971  
Transfer of systems from property, plant and equipment to inventory   $ -     $ 482,312  

 

See accompanying notes to Condensed Consolidated Financial Statements.

 

5

 

 

SS INNOVATIONS INTERNATIONAL, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – FINANCIAL STATEMENTS

 

Organization

 

SS Innovations International, Inc. (the “Company” or “SSi”) was incorporated as AVRA Surgical Microsystems, Inc. in the State of Florida on February 4, 2015. Effective November 5, 2015, the Company’s corporate name was changed to Avra Medical Robotics, Inc. (“AVRA”).

 

On April 14, 2023, a wholly owned subsidiary of the Company, AVRA-SSI Merger Corporation (“Merger Sub”) merged with CardioVentures, Inc., a Delaware corporation (“CardioVentures”), the indirect parent of Sudhir Srivastava Innovations Pvt. Ltd., an Indian private limited company engaged in the business of developing innovative surgical robotic technologies (“SSI-India”). As a result of the transaction, a “change in control” of the Company took place. In addition, among other matters, the Company changed its name to “SS Innovations International, Inc.” and implemented a one for ten reverse stock split.

 

The Transaction was accounted for as a recapitalization in accordance with GAAP (the “Recapitalization”). Under this method, AVRA was treated as the “acquired” company (the “Accounting Acquiree”) and Cardio Ventures Inc., the accounting acquirer, was assumed to have issued stock for the net assets of AVRA, accompanied by a recapitalization. Accordingly, for the year ended December 31, 2022, CardioVentures has been considered the ultimate holding company. Prior to October 18, 2022, Cardio Ventures Pvt Ltd., Bahamas (Cardio Bahamas), was in existence and served as the ultimate holding company. On October 18, 2022, Cardio Ventures Inc. acquired controlling interest in Otto Pvt Ltd. from Cardio Bahamas, making Cardio Ventures Inc. the ultimate holding company.

 

Effective April 25, 2025, the Company’s common stock was uplisted to the Nasdaq Stock Market LLC (“Nasdaq”), where it is listed for trading on the Nasdaq Capital Market under the ticker symbol “SSII.”

 

Transfer of Entity Under Common Control

 

On July 6, 2026, Dr. Sudhir Srivastava, the Company’s Chairman and Chief Executive Officer and controlling shareholder, transferred to the Company, for no consideration, his 99.9% ownership interest in SS International Centre for Robotics Surgery Private Limited (“SSICRS”). SSICRS is an Indian private limited company that provides classroom instruction and hands-on training in robotic-assisted surgery using the Company’s SSi Mantra surgical robotic system.

 

Dr. Sudhir Srivastava controlled SSICRS through his direct 99.9% ownership interest and controls the Company through Sushruta Pvt. Ltd., a company wholly owned by him whose Series A Preferred Stock represents more than 51% of the Company’s voting power. Accordingly, the Company and SSICRS were under common control immediately prior to the transfer.

 

The transfer was accounted for as a transaction between entities under common control in accordance with ASC 805-50. Accordingly, the assets and liabilities of SSICRS were recognized at their applicable historical carrying amounts, as adjusted to conform to U.S. GAAP and the Company’s accounting policies, and no gain or loss was recognized in connection with the transfer.

 

For the period from January 1, 2026 through September 30, 2026, SSICRS contributed approximately $ 41,825 revenue and net loss of $ 39,907 to the Company’s consolidated results of operations.

 

ASC 805-50 requires the financial statements presented for periods during which the entities were under common control to be retrospectively adjusted as though the entities had been combined for those periods. Management evaluated the effect of retrospectively including SSICRS in the Company’s historical financial statements from April 10, 2023, the inception of common control, and determined that the cumulative effect on accumulated deficit as of December 31, 2025 would have been approximately $18,358. Management evaluated the effect both quantitatively and qualitatively and concluded that it was immaterial to the Company’s previously reported consolidated financial statements. Accordingly, the Company has not retrospectively adjusted the comparative financial information for periods prior to 2026.

 

Basis of Presentation

 

Unaudited Interim Condensed Consolidated Financial Statements

 

The interim condensed consolidated balance sheet as of September 30, 2026, and the interim condensed consolidated statement of operations, comprehensive loss and stockholders’ equity for the three and nine months ended September 30, 2026 and September 30, 2025 and cash flows for the nine months ended September 30, 2026 and September 30, 2025 are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of our financial position as of September 30, 2026 and our results of operations for the three and nine months and cash flows for the nine months ended September 30, 2026 and September 30, 2025.

 

6

 

 

The financial data and other financial information disclosed in these notes to the interim condensed consolidated financial statements related to the three and nine months are also unaudited. The interim condensed consolidated results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any future annual or interim period. The condensed consolidated balance sheet as of December 31, 2025 included herein was produced from the audited consolidated financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2025 as filed by us with the SEC on March 10, 2026 and the Amendment included in the Form 10-K/A as filed by us with the SEC on March 31, 2026.

 

The interim condensed consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying condensed financial statements have been prepared on a consolidated basis and reflect the condensed consolidated financial statements of the Company and all of its subsidiaries.

 

The standalone financial statements of subsidiaries are fully consolidated on a line-by-line basis. Intra-group balances and transactions, and gains and losses arising from intra-group transactions, are eliminated while preparing condensed consolidated financial statements.

 

Accounting policies of the respective individual subsidiaries are aligned wherever necessary, so as to ensure consistency with the accounting policies that are adopted by the Company under U.S. GAAP.

 

Principles of Consolidation

 

The consolidated financial statements include our accounts and all majority-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The Company follows a monthly reporting calendar, with its fiscal year ending on December 31.

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform with the current presentation period.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis which implies the Company will continue to meet its obligations for the next 12 months as of the date these financial statements are issued. The Company had a working capital surplus of $36,934,343 and an accumulated deficit of $67,815,554 as of September 30, 2026. The Company also had net losses of $5,749,389 and $12,025,620 for three months and nine months ended September 30, 2026 respectively, which losses primarily resulted from non-cash items such as stock compensation expense of $2,153,984 and $7,476,455 for the three months and nine months ended September 30, 2026, and depreciation of $359,249 and $1,029,360 for the three months and nine months ended September 30, 2026 respectively. In addition, the Company has been dependent on related parties to fund operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited interim condensed consolidated financial statements are issued.

 

On March 6, 2026 (the “Closing Date”), the Company completed a private placement of its common stock which generated net proceeds of $18,446,498, after deducting offering expenses.

 

In the offering, the Company offered and sold a total of 5,774,839 shares of common stock consisting of:

 

  ● an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share for a total of $5,197,000 to directors, details of the same are as below:

 

  Ø 498,753 shares to Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer at $4.01 per share amounting to $2,000,000;

 

  Ø 501,253 shares to Dr. Frederic Moll, our Vice Chairman at $3.99 per share amounting to $2,000,000;

 

  Ø 300,000 shares to Tim Adams, a director at $3.99 per share amounting to $1,197,000; and

 

  ● an aggregate of 4,474,833 shares of common stock at $3.00 per share and total consideration of $13,424,498, to existing and new investors, led by Manipal Global Health Services, an existing shareholder.

 

7

 

 

On October 9, 2026, the Company completed a financing transaction in a private offering with an institutional investor pursuant to which it received gross proceeds of $20,000,000. In the financing, the Company issued a secured convertible promissory note to Growth Capital Partners, LLC, a Utah limited liability company, for principal amounting to $21,025,000 at a purchase price of $20,000,000. This note carries an original issue discount of $1,000,000. In addition, the Company agreed to pay $25,000 to the investor (Growth Capital Partners, LLC) to cover the investor’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of the note. The note bears interest at 8.75% per annum, compounded daily, matures 36 months from issuance, is convertible into common stock at 95% of the Market Price (as defined in the note), and is subject to monthly investor redemptions beginning 12 months after issuance, payable in cash or shares. The note is secured by the Company’s intellectual property and the assets of the Company and its intellectual property holding subsidiary, SSI IP Holdings, Inc., excluding the assets and capital stock of SSI-India, the Company’s Indian operating subsidiary.

 

SSi intends to use the net proceeds from this financing transaction for working capital and other general corporate purposes, which include, but are not limited to advancing the Company’s growth initiatives in India and other existing global markets and supporting preparation for entry into the United States and European Union markets.

 

However, the Company’s existing cash resources and income from operations are not expected to provide sufficient funds to carry out the Company’s operations and business development through the next twelve (12) months. The management of the Company is making efforts to raise further funding to scale up operations and meet its longer-term capital needs. While management of the Company believes that it will be successful in its capital formation and planned expansion of its operating activities, there can be no assurance that the Company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

  a) Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management. Significant estimates include fair value of stock options and standalone selling price in case of bundled revenue contracts.

 

  b) Cash and Cash Equivalents

  

The Company considers all highly liquid investments purchased with an original maturity of ninety days or less to be cash equivalents.

 

  c) Restricted Cash

 

Restricted cash includes any cash and cash equivalents that are legally restricted as to withdrawal or usage for the Company’s operations. For the purposes of the condensed consolidated statement of cash flows, the Company includes in its cash and cash-equivalent balances those amounts that have been classified as restricted cash and restricted cash equivalents.

  

  d) Accounts Receivable and Allowance for Expected Credit Losses

 

The Company’s account receivables are due from customers relating to contracts to supply surgical robotic systems, instruments, and accessories and to provide post sales warranty/maintenance services. The Company also sells surgical robotic systems under deferred payment arrangements and in such cases, the amounts due and recoverable beyond the one-year period at the balance sheet date are classified as long-term receivables. Collateral is currently not required. The Company also maintains credit loss allowance for estimated losses resulting from the inability of the Company’s customers to make payments. The Company periodically reviews these estimated allowances, including an analysis of the customers’ payment history and creditworthiness, the age of the trade receivable balances and current economic conditions that may affect a customer’s ability to make payments as well as historical collection trends for its customers as a whole. Based on this review, the Company specifically reserves for those accounts deemed uncollectible or likely to become uncollectible. When receivables are determined to be uncollectible, principal amounts of such receivables outstanding are deducted from the allowance.

 

8

 

 

  e) Employee Benefits

 

Contributions to defined contribution plans are charged to the condensed consolidated statement of operations and comprehensive loss in the period in which services are rendered by the covered employees. Current service costs for defined benefit plans are recognized in the period to which they relate. The liability in respect of defined benefit plans is calculated annually by the Company using the projected unit credit method. The Company records annual amounts relating to its defined benefit plans based on calculations that incorporate various actuarial and other assumptions, including discount rates, mortality, future compensation increases and attrition rates. The Company reviews its assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends when it is appropriate to do so. The effect of modifications to those assumptions is recorded in other comprehensive income (loss) (“OCI”) and amortized to net periodic benefit cost over the expected remaining period of service of the covered employees using the corridor method. The Company believes that the assumptions utilized in recording its obligations under its plans are reasonable based on its experience and market conditions. These assumptions may not be within the control of the Company and accordingly it is reasonably possible that these assumptions could change in future periods. The Company includes the service cost component of the net periodic benefit cost in the same line item or items as other compensation costs arising from services rendered by the respective employees during the period. The interest cost, expected return on plan assets and amortization of actuarial gains/loss, are included in “Other income, net”. Refer to Note 17 - Employee Benefit Plans to the unaudited interim condensed consolidated financial statements for details.

 

  f) Foreign Currency Translation

 

The Company’s reporting currency is U.S. dollars. The functional currency of the Company is the U.S. dollar. The functional currency of the Company’s subsidiary in India is Indian National Rupee (“INR”). Transactions denominated in INR are translated to U.S. dollars at rates which approximate those in effect on the transaction dates. Monetary assets and all liabilities denominated in foreign currencies on September 30, 2026 and September 30, 2025 are translated at the exchange rate in effect as of those dates. Stockholders’ equity is translated at the appropriate historical rates. Included in interest and other income is a foreign exchange gain resulting from such translations of approximately $63,085 and amount of $67,534 for the nine months ended September 30, 2026, and September 30, 2025, respectively.

 

The functional currency of each entity in the group is the currency of the primary economic environment in which it operates. Transactions in foreign currencies are initially recorded into functional currency at the rates of exchange prevailing on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are remeasured into functional currency at the rates of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are remeasured to the functional currency at exchange rates that prevailed on the date of inception of the transaction. All foreign exchange gains and losses arising on re-measurement are recorded in the Company’s condensed consolidated statement of operations and comprehensive loss.

 

The assets and liabilities of the subsidiaries for which the functional currency is other than the U.S. dollar are translated into U.S. dollars, the reporting currency, at the rate of exchange prevailing on the balance sheet date. Revenues and expenses are translated into U.S. dollars at the exchange rates prevailing on the last business day of each month, which approximates the average monthly exchange rate. Share capital and other equity items are translated at exchange rates that prevailed on the date of inception of the transaction. Resulting translation adjustments are included in “Accumulated other comprehensive income/(loss)” in the condensed consolidated balance sheet.

 

The relevant translation rates are as follows: for the nine months ended September 30, 2026 closing rate at 95.90 US$: INR, average rate at 92.93 US$:INR.

 

The relevant translation rates are as follows: for the nine months ended September 30, 2025 closing rate at 88.87 US$: INR, average rate at 87.23 US$:INR.

 

The relevant translation rates are as follows: for the year ended December 31, 2025 closing rate at 89.86 US$: INR, average rate at 87.72 US$:INR

 

9

 

 

  g) Inventory

 

The Company’s inventory consists of finished goods in the form of fully assembled and tested surgical robotic system, semi-finished goods in the form of various sub-systems of the surgical robotic systems in various stages of assembly and manufacturing and raw material in the form of various mechanical, electrical, and other material components, parts, motors, encoders etc. which are not yet assembled/manufactured. The inventory is valued at the lower of cost (first-in, first-out) or estimated net realizable value.

 

  h) Cost of Sales

 

Cost of sales primarily consists of manufacturing cost incurred for production of the Mantra System and the related instruments and accessories which are used to facilitate the use of the Mantra System. Further, Cost of sales also includes other costs such as salaries and rent which are directly attributable to the manufacturing process.

 

  i) Selling and Administrative Expenses

 

Selling and administrative expenses primarily consist of indirect expenses which are not directly attributable to any other identified expense category of the Company.

 

  j) Fair value measurements

 

ASC Topic 820, Fair Value Measurements and Disclosures defines fair value as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability as against assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk, including the Company’s own credit risk. The fair value hierarchy consists of the following three levels:

 

  ● Level I — Quoted prices for identical instruments in active markets.

 

  ● Level II — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

 

  ● Level III — Instruments whose significant value drivers are unobservable.

 

  k) Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. and cash equivalents, time deposits and accounts receivable. By their nature, all such financial instruments involve risks including the credit risks of non-performance by counterparties. The surplus funds are maintained as cash and cash equivalents and time deposits, placed with highly rated financial institutions to reduce its exposure to market risk with regard to these funds. The Company’s exposure to credit risk on account receivable is influenced mainly by the individual characteristic of each customer and the concentration of risk from the top few customers. To mitigate this risk the Company evaluates the creditworthiness of its customers in conjunction with its revenue recognition processes as well as through its ongoing collectability assessment processes for accounts receivable. The Company does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

 

10

 

 

  l) Commitments and Contingencies

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recognized when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. A disclosure for a contingent liability is made when there is a possible obligation that may require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Legal costs incurred in connection with such liabilities are expensed as incurred. Capital commitments are disclosed in the condensed consolidated financial statements.

  

  m) Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification, or ASC606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized:

 

  ● Identification of a contract with a customer or placement of a purchase order by the customer.

 

  ● Identification of the performance obligations in the contract or the purchase order as the case may be.

 

  ● Determination of the transaction price which is reflected in the purchase order placed by the customer.

 

  ● Allocation of the transaction price to the performance obligations in the contract; and

 

  ● Recognition of revenue when or as the performance obligations are satisfied as per the terms of the purchase order received from the customer.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Product type and payment terms vary by client.

 

System Sales:

 

The Company recognizes revenue when the “transfer of control” occurs, which typically takes place upon the delivery of the system to the customer. In cases where a deferred payment arrangement exists, revenue is recognized at the present value of the consideration receivable, adjusted by the present value of any extended warranty obligations.

 

Standalone Selling Price:

 

The Company’s system sale arrangements contain multiple products and services, including system, accessories, instruments and services. Other than services, the Company generally deliver all of the products upfront. Each of these products and services is a distinct performance obligation. System, instruments, accessories and services are also sold on a standalone basis. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling prices considering market conditions and entity-specific factors including, but not limited to, historical pricing data, features and functionality of the products and services and industry benchmark. The Company regularly reviews standalone selling prices and maintains internal controls over establishing and updating these estimates. Revenue that is allocated to the service obligation is deferred and recognized ratably over the service period upon expiration of first year of service which is free and included in the system sale arrangements.

 

11

 

 

Key Terms of Customer Contracts

 

The Company enters into binding contracts with customers through either an agreement or a sales order, with all terms and conditions mutually agreed upon by both parties. The key terms and conditions include:

 

  1. Finalization of Product and Price: Agreement on the specific model of the “SSI Mantra” system and its selling price.

 

  2. Payment Terms: Determination of payment terms, which may involve either a deferred payment arrangement or a one-time payment upon delivery and installation of the system at the customer’s premises.
     
  3. Deferred Payment Model: For deferred payments, customers typically pay an advance amount before the dispatch of the system. The remaining balance is payable in yearly installments over a period of 3 to 5 years. Present value of deferred payment is calculated using the prevailing interest rate.

 

  4. Warranty Services: Instead of negotiating the sales price, the Company provides a warranty service that includes a 1-year assurance warranty and an extended warranty for an additional 3 to 5 years. The exact terms are mutually agreed upon with the customer.

 

  5. Delivery, Installation, and Training: The Company is responsible for delivering and installing the system at the customer’s premises. Post-installation, the Company provides free training to surgeons and surgical staff to enable them to operate the system effectively. With respect to the sale of surgical robotic systems, training is provided at the time of delivery to the end customer, however the effort involved is considered negligible.

 

  6. Transfer of Risk and Rewards: The risks and rewards associated with the system are transferred to the customer upon delivery to their premises.

 

Instrument and Accessories Sales:

 

The Company also sells instruments for use by surgeons in conjunction with the use of its surgical robotic systems. These instruments are consumable items for our hospital customers, and the Company recognizes the revenues from the sale of instruments as and when the instruments are delivered to the customer.

 

Warranty and Annual Maintenance Contract Sales:

 

By application of ASC 606, a portion of the equipment sales value which is attributable towards the component of annual maintenance contracts is shown separately as Warranty sales. Once the assurance warranty or standard warranty periods are over, the maintenance contracts become effective and actual income from maintenance contracts is recognized as a distinct revenue stream.

 

Lease Income:

 

Under ASC 842, in cases where the systems are installed on a pay per procedure basis, the Company earns revenue which is a mix of fixed and variable components. Variable component consists of revenue share which is agreed based on the number and type of procedures performed by the customer, while the fixed component involves an agreed amount which the customer is obliged to pay over the lease term. Accordingly, the fixed component is recognized on a straight-line basis as lease income. Since the title to the system is not getting transferred to the counterparty, hence the cost relating to those systems is capitalized under property, plant and equipment and accordingly depreciation is charged over its period of useful life.

 

Training Income:

 

Training revenue represents fees earned from surgeon training, clinical education programs, workshops, and related professional services. Revenue is recognized as the training services are provided and the related performance obligations are satisfied.

 

  n) Property Plant & Equipment

 

Property, plant, and equipment are stated at cost, which is generally comprised of the purchase price for such property, plant, or equipment, non-refundable duties and taxes, Installation cost, freight, other associated costs, but excludes any discounts and/or rebates, less accumulated depreciation and impairment.

 

The Company reviews property, plant, and equipment for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. 

 

12

 

 

Property Plant and Equipment are depreciated using the straight-line method at rates determined as per estimated useful life of the assets. The estimated useful lives used in calculating depreciation are as follows: 

 

    Years  
Computer & peripherals     3  
Furniture     5  
Leasehold improvement     4-8  
Office equipment     5  
Plant and machinery     8  
Server & networking     3-6  
Vehicles     5  
Pay per use systems     10  
Demo system     10  

 

  o) Long-lived Assets

 

In accordance with ASC 360, “Property Plant and Equipment”, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset and current expectation that the asset will more than likely not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value which is generally determined based on the sum of the discounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain circumstances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

  

  p) Stock-based Compensation Expense

 

Under the fair value recognition provisions of ASC Topic 718, Compensation-Stock Compensation, cost is measured at the grant date based on the fair value of the award and is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

Determining the fair value of stock-based awards at the grant date requires significant judgment, including estimating the expected term over which the stock awards will be outstanding before they are exercised and the expected volatility of our stock.

 

Stock Options: These provide employees with the right, but not the obligation, to purchase shares of the Company’s stock at a specified price within a defined period, as per the terms of the stock option agreement. Stock-based compensation expense associated with AVRA 2016 Stock Incentive Plan is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering period and recognized over that offering period.

 

Stock Awards (Restricted Stock Awards, or RSAs): These do not require the employee to exercise any options. Each stock unit automatically converts into a specified number of shares upon vesting. The Company uses last three months’ average share price of common stock on OTC (prior to April 24, 2025) or on Nasdaq (subsequent to April 24, 2025) as grant date fair value for RSUs.

 

The Company recognizes stock-based compensation expense in the condensed consolidated statement of operations and comprehensive loss for both employees and non-employee directors based on the grant-date fair value of the awards. These costs are recognized on a straight-line basis over the requisite service period, or until the date at which the recipient becomes eligible for retirement, if shorter. Forfeitures of equity awards are accounted for as they occur.

 

The Company accounts for equity instruments issued in exchange for goods or services from non-employees in accordance with ASC Topic 718 Stock Compensation. The costs associated with these equity instruments are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable.

 

13

 

 

  q) Income Taxes

 

The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carry forwards. The carrying amounts of deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed periodically based on the more-likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses, the duration of statutory carry forward periods, and tax planning alternatives. The Company uses a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals and litigation processes, if any. The second step is to measure the largest amount of tax benefit as the largest amount that is more likely than not to be realized upon settlement. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. 

 

The Company determines the tax provision for interim periods using an estimate of its annual effective tax rate. Each quarter, the Company updates its estimate of annual effective tax rate for India Jurisdiction, and if its estimated tax rate changes, the Company makes a cumulative adjustment.

 

Management judgment is required in determining provision for income taxes, deferred tax assets and liabilities, tax contingencies, unrecognized tax benefits, and any required valuation allowance, including taking into consideration the probability of the tax contingencies being incurred. Management assesses this probability based upon information provided by its tax advisers, its legal advisers and similar tax cases. If at a later time the assessment of the probability of these tax contingencies changes, accrual for such tax uncertainties may increase or decrease.

  

The Company has a valuation allowance due to management’s overall assessment of risks and uncertainties related to its future ability in the U.S. to realize and, hence, utilize certain deferred tax assets, primarily consisting of net operating losses (“NOLs”), carry forward temporary differences and future tax deductions.

 

The effective tax rate for annual and interim reporting periods could be impacted if uncertain tax positions that are not recognized are settled at an amount which differs from the Company’s estimate. Finally, if the Company is impacted by a change in the valuation allowance resulting from a change in judgment regarding the realizability of deferred tax assets, such effect will be recognized in the interim period in which the change occurs.

 

  r) Basic and Diluted Loss per Share

 

The following table sets forth the computation of basic and diluted earnings per share: 

 

    For the three months ended  
    September 30,
2026
    September 30,
2025
 
             
Net loss (a)   $      (5,749,389 )   $        (3,717,964 )
Basic weighted average common shares outstanding (b)     200,377,964       193,589,845  
Dilutive effect of stock-based awards     9,273,838       9,266,656  
Diluted weighted average common shares outstanding     209,651,802       202,856,501  
                 
Earnings per share attributable to SS Innovations International, Inc. stockholders:                
                 
Basic and Diluted (a)/(b)   $ (0.03 )   $ (0.02 )

 

14

 

 

    For the nine months ended  
    September 30,
2026
    September 30,
2025
 
             
Net loss (a)   $      (12,025,620 )   $        (9,656,008 )
Basic weighted average common shares outstanding (b)     198,856,670       188,720,115  
Dilutive effect of stock-based awards     9,273,838       9,259,623  
Diluted weighted average common shares outstanding     208,130,508       197,979,738  
                 
Basic and Diluted (a)/(b)   $ (0.06 )   $ (0.05 )

 

Basic net loss per share is calculated by dividing the net loss attributable to SSi stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. 

 

  s) Research and Development Costs

 

In accordance with ASC Topic 730 Research and development costs are expensed as incurred and include costs of material, salaries, benefits and other headcount-related costs, contract and other outside service fees, and facilities and overhead costs.

 

  t) Fair Value of Financial Instruments

 

The Company’s financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items. 

 

  u) Recent Accounting Pronouncements

 

In November 2024, FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), which requires entities to disaggregate any relevant expense caption presented on the face of the income statement within continuing operations into the following required natural expense categories, as applicable: (1) purchases of inventory, (2) employee compensation, (3) depreciation, (4) intangible asset amortization, and (5) depreciation, depletion, and amortization recognized as part of oil- and gas-producing activities or other depletion expenses. An entity’s share of earnings or losses from investments accounted for under the equity method is not a relevant expense caption that requires disaggregation. Such ASU’s amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this pronouncement on its disclosures and our condensed consolidated financial statements.

 

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (“ASC Topic 270”): Narrow-Scope Improvements. This ASU provides a comprehensive list of interim disclosures that are required by U.S. GAAP and incorporates disclosure principle of material events or changes occurred since the prior year-end. The ASU will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its condensed consolidated financial statements.

 

15

 

 

In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments-Credit Losses (“ASC Topic 326”): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This ASU provides a practical expedient when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC Topic 606. The ASU will be effective for annual reporting periods beginning after December 15, 2025, including interim periods within those years, with early adoption permitted. The Company has adopted this ASU beginning January 1, 2026. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements and disclosures.

  

  v) Leases

 

The Company determines if an arrangement is a lease at inception of the contract. The Company’s assessment is based on whether: (1) the contract involves the use of a distinct identified asset, (2) the Company obtains the right to substantially all the economic benefit from the use of the asset throughout the term of the contract, and (3) the Company has the right to direct the use of the asset. A lease is classified as a finance lease if any one of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset or (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset.

 

Operating leases are presented within “Right-of-use assets, operating lease” “Current portion of operating lease liabilities” and “Operating lease liabilities, less current portion” in the Company’s condensed consolidated balance sheet.

 

Right-of-use (ROU) assets represent the Company’s right to use an underlying asset during the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease arrangement. Lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Operating lease ROU assets are recognized at commencement date in an amount equal to lease liability, adjusted for any lease prepayments, initial direct costs, and lease incentives. For leases in which the rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rate based on the information available at commencement date. The Company determines the incremental borrowing rate by adjusting the benchmark reference rates with appropriate financing spreads applicable to the respective geographies where the leases are entered and lease specific adjustments for the effects of collateral, if applicable. Lease terms include the effects of options to extend or terminate the lease when it is reasonably certain at commencement of the lease that the Company will exercise that option. Lease expense for operating lease arrangements is recognized on a straight-line basis over the lease term reflecting single operating lease cost. The Company evaluates lease agreements to determine lease and non-lease components, which are accounted for separately.

 

Lease payments that depend on factors other than an index or rate are considered variable lease payments and are excluded from the operating lease assets and liabilities and are recognized as expense in the period in which the obligation is incurred. Lease payments include payments for common area maintenance, utilities such as electricity, heating and water, among others, and property taxes, and other similar payments paid to the landlord, which are treated as non-lease component.

 

The Company accounts for lease-related concessions in accordance with guidance in Topic 842, Leases, to determine, on a lease-by-lease basis, whether the concession provided by lessor should be accounted for as a lease modification.

 

The Company accounts for a modification as a separate contract when it grants an additional right of use not included in the original lease and the increase is commensurate with the standalone price for the additional right of use, adjusted for the circumstances of the particular contract. Modifications which are not accounted for as a separate contract are reassessed as of the effective date of the modification based on its modified terms and conditions and the facts and circumstances as of that date. Upon modification, the Company remeasures the lease liability to reflect changes to the remaining lease payments and discount rates and recognizes the amount of the remeasurement of the lease liability as an adjustment to the ROU assets. However, if the carrying amount of the ROU assets is reduced to zero as a result of modification, any remaining amount of the remeasurement is recognized as an expense in condensed consolidated statement of operations and comprehensive loss.

 

The Company reviews ROU assets for impairment whenever events or changes in circumstances indicate that the related carrying amount may not be recoverable.

 

16

 

 

Sales-type Leases

 

Lease Classification

 

In determining whether a transaction should be classified as a sales-type or operating lease (whether fixed-payment or usage-based), the Company considers the following terms at lease commencement: (1) whether title of the system transfers automatically or for a nominal fee by the end of the lease term; (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased system; (3) whether the lease term is for the major part of the remaining economic life of the leased system; (4) whether the lease grants the lessee an option to purchase the leased system that the lessee is reasonably certain to exercise; and (5) whether the underlying system is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. However, if classifying a lease as a sales-type lease would result in a selling loss at commencement (day-one selling loss), the Company classifies such lease as an operating lease.

 

Derecognition and Selling Profit

 

At the commencement date of a qualifying sales-type lease, the Company derecognizes the underlying asset and recognizes a net investment in the lease, which includes (i) the present value of future lease payments, (ii) any guaranteed or unguaranteed residual value, and (iii) unearned interest income. The resulting selling profit or loss is measured as the difference between the net investment in the lease and the carrying amount of the derecognized asset.

 

Variable lease payments

 

Variable lease payments under the arrangement do not depend on an index or a rate but are instead based on the customer’s actual usage of the leased equipment or related surgical activity. Because such payments are usage-based, they are excluded from the initial measurement of the lease. SSi recognizes these variable amounts as revenue in the period in which the underlying surgical procedures occur, consistent with the terms of the pay-per-use arrangement.

  

Interest Income Recognition

 

Interest income on sales-type leases is recognized using the rate implicit in the lease so as to produce a constant periodic rate of return on the net investment.

 

Credit Losses

 

The Company applies the current expected credit loss (“CECL”) model to its net investment in sales-type leases. Expected credit losses are estimated based on historical loss experience, current conditions, and reasonable and supportable forecasts. The allowance for credit losses is reassessed each reporting period and included as a contra-asset to the net investment in sales-type leases.

 

w) Common Control Transactions

 

The Company accounts for transactions between entities under common control in accordance with ASC 805-50, Transactions Between Entities Under Common Control. Assets and liabilities acquired in a common control transaction are recognized at their historical carrying amounts, and no goodwill or fair value adjustments are recognized.

 

ASC 805-50 require retrospective presentation of the financial statements for periods during which the entities were under common control as if the entities had been combined for those periods. The Company evaluated the impact of retrospectively including the historical financial statements of SS International Centre for Robotics Surgery Private Limited (“SSICRS”) from April 10, 2023, the date common control was established. Based on management’s assessment of both quantitative and qualitative factors, the effect on the Company’s previously issued consolidated financial statements for periods prior to January 1, 2026 was determined to be immaterial. Accordingly, the Company has not retrospectively adjusted comparative financial information for periods prior to 2026.

 

Beginning January 1, 2026, the accompanying condensed consolidated financial statements include the historical assets, liabilities, results of operations, and cash flows of SSICRS in accordance with the guidance applicable to transactions between entities under common control.

 

Comprehensive Loss

 

Comprehensive loss consists of net loss and other gains and losses affecting stockholders’ equity that, under GAAP, are excluded from net loss. Other comprehensive loss represents foreign currency translation adjustment attributable to Indian operations. Refer to Consolidated Statements of Comprehensive Loss. Total foreign currency transaction gains and losses were immaterial for the three and nine months ended September 30, 2026, and 2025.

 

17

 

 

NOTE 3 – SEGMENT INFORMATION

 

The Company is focused on designing, manufacturing and marketing an advanced, next-generation and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The Company is committed to accelerating access to surgical robotics technologies in all parts of the world and particularly in underserved regions through a comprehensive ecosystem of providing an affordable surgical robotic system, its related instruments and accessories backed up by clinical, field service and maintenance support also provided by the Company. The systems as well as instruments and accessories are primarily designed, developed and manufactured by the Company in its manufacturing facility located in India.

 

During the three months ended September 30, 2026, and 2025, the Company’s revenue from within India accounted for 97% and 94% of total revenue, respectively, while revenue from the Company’s markets outside India accounted for 3% and 6% of total revenue, respectively. During the nine months ended September 30, 2026, and 2025, the Company’s revenues from within India accounted for 94% and 85% of total revenue, respectively, while revenue from the Company’s markets outside India accounted for 6% and 15% of total revenue, respectively. The Company manages the business activities on a consolidated basis and operates in one reportable segment. The Company’s determination that it operates as a single operating segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.

 

The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM utilizes the Company’s long-range plan, which includes product development, technology refinement plans and long-range selling and financial models, as a key input to resource allocation. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using gross margins and net income / loss from operations.

 

Significant segment expenses within income from operations, as well as within net income / loss, include cost of revenue, research and development, and selling, general and administrative expenses, which are each separately presented on the Company’s Consolidated Statements of Operations. Other segment items within net income include interest and other income, net, and income tax expense.

 

The Company’s long-lived assets consist primarily of property, plant and equipment. As of September 30, 2026 and December 31, 2025, 94% of long-lived assets were in India and 6% were outside India.

 

NOTE 4 – PROPERTY, PLANT AND EQUIPMENT, NET

 

The Company’s property, plant and equipment consisted of the following as of:

 

    September 30,
2026
    December 31,
2025
 
Gross Amount            
Computer & peripheral   $            517,230     $            485,125  
Furniture     319,495       335,664  
Leasehold improvement     692,415       738,955  
Office equipment     409,635       405,993  
Pay Per Use Systems     6,194,923       5,368,388  
Plant and machinery     870,921       592,426  
Server & networking     38,208       40,380  
Vehicles     769,416       680,211  
Demo system     2,117,066       1,999,327  
Capital work in progress     277,576       -  
Accumulated depreciation     (2,446,379 )     (1,545,923 )
Total   $ 9,760,506     $ 9,100,546  

 

Depreciation expense for the three months ended September 30, 2026, and 2025 amounted to $359,249 and $297,173, respectively.

 

Depreciation expense for the nine months ended September 30, 2026, and 2025 amounted to $1,029,360 and $766,416, respectively.

 

The Company deployed nine systems for demonstration purposes. As of September 30, 2026, five systems were located at the Company’s premises, and four systems were installed at a partner’s facility. These systems remain under the Company’s ownership and control and are therefore capitalized as property, plant, and equipment in accordance with ASC 360. 

 

18

 

 

NOTE 5 – NET INVESTMENT IN SALE-TYPE LEASE

 

Measurement of net investment

 

The components of the Company’s investments in sales-type leases, net is as follows:

 

    September 30,
2026
    December 31,
2025
 
Gross lease receivables   $            3,952,797     $            2,122,950  
Unearned income     (999,024 )     (502,775 )
Subtotal     2,953,773       1,620,175  
Allowance for credit loss     -       -  
Net investment in sales-type leases   $ 2,953,773     $ 1,620,175  

 

The net investment in sales-type leases was classified in the consolidated balance sheets as follows:

 

    September 30,
2026
    December 31,
2025
 
Other Current Assets   $            583,830     $            209,586  
Long-term investment in sales-type leases, net     2,369,943       1,410,589  
Net investment in sales-type leases   $ 2,953,773     $ 1,620,175  

 

Interest income recognition

 

Interest income under sales-type leases during nine months ended September 30, 2026 were as follows:

 

    September 30,
2026
    September 30,
2025
 
Interest income   $ 123,470       -  

 

Maturity analysis of lease receivables

 

The following table presents the undiscounted cash flows related to gross lease receivables as of September 30, 2026

 

    September 30,
2026
    December 31,
2025
 
2026, excluding the nine months ended September 30, 2026   $            189,478     $            311,245  
2027     546,762       339,235  
2028     584,183       345,992  
2029     610,348       356,127  
2030     477,233       206,571  
2031 and thereafter     1,344,982       530,534  
Total   $ 3,752,986     $ 2,089,704  

 

19

 

 

NOTE 6 – ACCOUNTS RECEIVABLE, NET

 

Accounts receivable, net consists of the following as of: 

 

    September 30,
2026
    December 31,
2025
 
             
Accounts receivable, net   $       16,764,399     $        12,398,542  
Accounts receivable, net (non-current)     7,314,087       8,566,654  
    $ 24,078,486     $ 20,965,196  

 

The Company performed an analysis of the trade receivables related to SSI India and determined, based on the deferred payment terms of the contracts, that a $ 7,314,087 and $8,566,654 as of September 30, 2026 and December 31, 2025, respectively, may not be due and collectible within one year and thus the Company classified these receivables as non-current.

 

Activity in the allowance for the credit losses for the three and nine months ended September 30, 2026 and 2025 is as follows:

 

    For the three months
period ended
 
    September 30,
2026
    September 30,
2025
 
             
Balance at the beginning of the year   $         1,158,761     $         377,722  
Additions / (Reversals)     237,134       471,040  
Foreign currency translation adjustment     (23,686 )     (5,603 )
Balance at the end of the year   $ 1,372,209     $ 843,159  

 

    For the nine months
period ended
 
    September 30,
2026
    September 30,
2025
 
             
Balance at the beginning of the year   $            896,180     $            545,799  
Additions / (Reversals)     548,608       302,963  
Foreign currency translation adjustment     (72,579 )     (5,603 )
Balance at the end of the year   $ 1,372,209     $ 843,159  

 

Details of customers which accounted for 10% or more of total revenues during the three and nine months ended September 30, 2026, and September 30, 2025 and 10% or more of total accounts receivables as at September 30, 2026, and December 31, 2025 are as follows:

 

    Percentage of revenue
For the three months ended
    Percentage of revenue
For the nine months ended
    Percentage of Accounts
Receivables As at
 
    September 30,
2026
    September 30,
2025
    September 30,
2026
    September 30,
2025
    September 30,
2026
    December 31,
2025
 
Customer A            12 %                                 -                                   3 %                                 -                                   3 %                                 -  

 

20

 

 

NOTE 7 – CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

For the purpose of condensed consolidated statement of cash flows, cash, cash equivalents and restricted cash (current & non-current) consists of the following as of:

 

        September 30,
2026
    December 31,
2025
 
                 
Cash and cash equivalents        $ 8,113,767      $ 3,206,406  
                     
Fixed Deposit   Lien Against Overdraft Facility            10,038,021              5,922,160  
    Lien Against Bank Guarantee     83,300       43  
    Lien Against Credit Card Facility     -       15,447  
Restricted cash (Current)         10,121,321       5,937,650  
                     
Fixed Deposit   Lien Against Bank Guarantee     352,349       458,964  
    Lien Against Credit Card Facility     17,496       -  
Restricted cash (Non-current)         369,845       458,964  
                     
Total Cash, cash equivalents and restricted cash        $ 18,604,933      $ 9,603,020  

 

The Company has classified fixed deposits (FDs), which are subject to withdrawal restrictions, as Restricted cash. Additionally, time deposits with remaining maturity of over one year have been classified as non-current.

 

The Company has secured a bank overdraft facility from HDFC and ICICI Bank, collateralized by fixed deposits held with HDFC Bank. This facility includes a withdrawal restriction tied to the fixed deposit. (Refer Note 11 – Debt.)

 

NOTE 8 – PREPAID, CURRENT AND NON-CURRENT ASSETS

 

Prepaid, current and non-current assets consists of the following as of:

 

    September 30,
2026
    December 31,
2025
 
             
Balances from statutory authorities   $ 8,113,907     $ 5,622,738  
Prepaid expense- stock compensation current     1,292,885       1,157,911  
Net investment in sale type lease- current*     583,830       209,586  
Security deposits     496,726       338,493  
Other prepaid- current assets#                   3,071,791              2,838,095  
Prepaid and other current assets     13,559,139       10,166,823  
                 
Prepaid expense- stock compensation non-current     1,896,589       2,255,358  
Net investment in sale type lease- non-current*     2,369,943       1,410,589  
Security deposits     238,484       248,027  
Other prepaid- non-current assets     153,433       124,909  
Prepaid and other non-current assets     4,658,449       4,038,883  
                 
Total prepaid, current and non-current assets   $ 18,217,588     $ 14,205,706  

 

* Refer to Note-5 for Net investment in sale type lease.

  

# Includes Related Party Balances, refer Note-20.

 

Prepaid expenses – stock-based compensation represents unamortized portion of common stock granted to advisors for services to be rendered by them in future. (Refer to Note 19 – Stock-based Compensation Expenses).

 

21

 

 

NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES & OTHER CURRENT LIABILITIES

 

Accounts payable and accrued expenses & other current liabilities consists of the following as of:

 

    September 30,
2026
    December 31,
2025
 
             
Accounts payable   $ 6,328,993     $ 5,127,193  
                 
Accrued expenses & other current liabilities:                
Payable to statutory authorities     126,243       91,393  
Client liabilities     589,132       104,696  
Salary payable     32,283       21,548  
Other accrued liabilities#                   5,252,898                  5,608,065  
Total accrued expenses & other current liabilities     6,000,556       5,825,702  
                 
Other non-current liabilities:                
Provision for Gratuity Long term     252,630       188,622  
Other accrued liabilities     372,599       100,142  
Total other non-current liabilities     625,229       288,764  
                 
Total accounts payable, accrued current & other liabilities   $ 12,954,778     $ 11,241,659  

 

Accounts payable at $6,328,993 as of September 30, 2026 (December 31, 2025: $5,127,193), reflect the amounts due to various vendors of supplies and services in the normal course of business operations. Other accrued liabilities of $5,252,898 as of September 30, 2026 (December 31, 2025: $5,608,065) mainly include accrued expenses of $1,256,248 (December 31, 2025: $1,072,596) and income tax provision of $3,727,382 (December 31, 2025: $4,214,339).

 

# Includes Related Party Balances, refer Note 20.

 

NOTE 10 – NOTES PAYABLE

 

In January 2025, the Company raised $28,000,000 from its affiliate by the issuance of a One-Year 7% Convertible Promissory Notes to finance its ongoing working capital requirements. These Notes were payable in full after 12 months from the respective date of issuance of these Notes and were convertible at the election of the noteholder at any time through the maturity date at a per share price of $1.38.

 

In February 2025, the Company paid $4,212,637 towards repayment of five 7% One-Year Promissory Notes totaling $4,000,000 in principal amount raised from Sushruta Pvt Ltd., an affiliate, on various dates during 2024, along with interest due thereon.

 

In February 2025, the Company paid $1,068,849 towards repayment of one 7% One-Year Convertible Promissory Note of $1,000,000 in principal amount issued to an investor in February 2024 along with the interest due thereon.

 

In February 2025, the Company converted three 7% One Year Convertible Promissory Notes totaling $450,000 issued to several investors in February 2024, along with the interest accrued thereon, into 108,048 shares of common stock the Company as per the conversion rights exercised by the note holders.

 

In February 2025, the Company converted Convertible Notes totaling $22,000,000, in principal amount, along with the interest accrued thereon, issued to Sushruta Pvt Ltd. into 16,046,814 shares of common stock of the Company.

 

In March 2025, the Company converted Convertible Notes totaling $8,000,000 in principal amount, along with the interest accrued thereon, issued to Sushruta Pvt Ltd into 5,811,554 shares of common stock of the Company.

 

Refer to Note 20 for Related Party Balances.

 

22

 

 

NOTE 11 – DEBT

 

The Company’s debt consists of the following as of:

 

    September 30,     December 31,  
    2026     2025  
Revolving Credit Facility            
-HDFC Bank Ltd Overdraft (OD1)(1)   $      1,396,418     $      4,829,115  
-HDFC Bank Ltd Overdraft (OD2)(2)     1,003,458       493,355  
-HDFC Bank Ltd (WCDL 1)(1)     4,170,915       -  
-HDFC Bank Ltd (WCDL 2)(2)     6,256,372       6,120,478  
-ICICI Bank Overdraft (OD3)(3)     4,060,706       -  
ECLGHS - Working capital Term Loan(5)     1,251,274       -  
Total Debt     18,139,143       11,442,948  
Less: Revolving Credit Facility     16,887,869       11,442,948  
Less: Current portion of ECLGHS - Working capital Term loan     52,136       -  
Long-term debt, net of current portion   $ 1,199,138       -  

 

1. The HDFC Bank revolving credit facility includes overdraft facility and working capital demand loan. During the period ended September 30, 2026, the company has converted $4,170,915 of overdraft facility into working capital demand loan. The facility was availed against a lien on fixed deposits totaling $6,234,632 provided by the Company to HDFC Bank. The working capital demand loan is sanctioned at an interest rate of 8.50% (linked with 1-month Repo rate) per annum on the working capital overdraft limit, with interest payable monthly on the first day of the subsequent month and principal repayable within six months. Overdraft facility against fixed deposits has an interest rate of 8.65% (linked with 1-month Repo rate plus 3.4%), payable at monthly intervals on the first day of the following month and principal repayable on demand.

 

2. The HDFC Bank revolving credit facility includes overdraft facility and working capital demand loan. During the period ended September 30, 2026, the company has converted $6,256,372 of overdraft facility into working capital demand loan. The facility is secured by a charge over all current assets, plant, and machinery of the Company, as well as a lien on fixed deposits of $17,07,501 in favour of HDFC Bank. The working capital demand loan has an interest rate of 8.50% (linked with 1-month Repo rate) per annum on the working capital overdraft limit, with interest payable monthly on the first day of the subsequent month and principal repayable within six months. Overdraft facility against fixed deposits has an interest rate of 1.25% over and above prevailing rate of interest on fixed deposits, payable at monthly intervals on the first day of the following month and principal repayable on demand. In October 2025, the Company converted its overdraft facility into a short-term working capital demand loan (“WCDL”) repayable on demand for a period of six months (OD3). The WCDL is secured against the lien on fixed deposits of $656,296 in favor of HDFC Bank. Upon the maturity of the working capital demand loan (“WCDL”) facility in April 2026, the Company converted the facility back into an overdraft facility with HDFC Bank. Accordingly, the outstanding balance under the facility as of the balance sheet date is included in the HDFC Bank overdraft facility (OD2). The overdraft facility continues to be secured by a lien on fixed deposits of $656,296 maintained with HDFC Bank.

 

3. During the period ended September 30, 2026, the Company availed overdraft facilities from ICICI Bank amounting to $4,060,706, which are secured against a lien on fixed deposits aggregating to $2,095,885 maintained by the Company. In addition, the overdraft facilities are secured by a charge over all current assets and movable fixed assets of the Company and are further supported by the personal guarantees of Dr. Sudhir Prem Srivastava, Dr. Vishwajyoti P. Srivastava and Akshay Srivastava. The said overdraft facilities carry an interest rate linked to the Repo Rate plus 3.65% per annum, with interest payable on or before the 2nd day of each successive month and principal repayable on demand in next one year.

 

4. Additionally, both credit revolving facilities are secured by personal guarantees provided both by Dr. Sudhir Prem Srivastava and Dr. Vishwajyoti P Srivastava. As of September 30, 2026, and December 31, 2025, the Company was in compliance with all financial and non-financial covenants under the bank overdraft facility agreements.

 

5. During the period ended September 30, 2026, as per the terms of Government of India “Emergency Credit Line Guaranteed Scheme (ECLGS) 5.0 (“Scheme”) and Operational Guidelines (“Guidelines”) issued by National Credit Guarantee Trustee Company Ltd (NCGTCL/Trustee) dated May 8, 2026, the company has obtained Emergency Credit Line Guaranteed (ECLG), by way of Working Capital Term loan (WCTL) on 24th July 2026 which is covered by 100% credit guarantee from National Credit Guarantee Trustee Company Ltd (NCGTC) - Ministry of Finance, Government of India. The term loan has an interest rate of 8.80% p.a. and is repayable in scheduled forty-eight monthly instalments of $26,068 starting August 26, 2027 (after one year moratorium). The facility is subject to customary terms and conditions and is guaranteed in accordance with the ECLGS framework. As of September 30, 2026, the outstanding principal balance under the facility was $1,251,274, of which $52,136 was classified as current and $1,199,138 was classified as non-current in the accompanying condensed consolidated balance sheet.

 

23

 

 

NOTE 12 – DEFERRED REVENUE

 

Contract liabilities (deferred revenue) consist of advance billings and billing in excess of revenues recognized. Deferred revenue also includes the amount for which services have been rendered but other conditions of revenue recognition are not met, for example, where the Company does not have an enforceable contract.

 

The revenues attributable to the warranty are recognized over the period to which it relates. During the three and nine months ended September 30, 2026, the Company had sold eleven and fifty-four surgical robotic systems, respectively. The revenues attributable to warranty for the agreed warranty period with respect to each of the sales contracts are deferred for recognition over the period to which it relates.

 

In case of systems sold on a deferred payment basis, the present value of the invoiced system sales, realizable over the deferred payment period, is recognized as system sales. The difference between the invoiced amount and its present value is adjusted (reduced) in the accounts receivable balance. This difference is recorded as interest income under other income, with a corresponding impact on accounts receivable over the collection period of contract. The Company recorded $824,676 and $290,753 as interest income on account of deferred financing component during the nine months period ended September 30, 2026 and September 30, 2025 respectively.

 

    September 30,
2026
    December 31,
2025
 
             
Deferred revenue- beginning of period   $          10,406,493     $          6,452,555  
Additions     4,369,762       6,472,933  
Net changes in liability for pre-existing contracts     14,776,255       12,925,488  
Revenue recognized for system sales     -       407,118  
Revenue recognized for instrument sales     1,021,899       1,233,482  
Revenue recognized for warranty sales     1,313,542       878,395  
Deferred revenue- end of period   $ 12,440,814     $ 10,406,493  
                 
Deferred revenue expected to be recognized in:                
One year or less   $

3,720,231

    $ 3,266,686  
More than one year     8,720,583       7,139,807  
    $ 12,440,814     $ 10,406,493  

 

For the three months ended September 30, 2026 and 2025:

 

The following table disaggregates our revenue by major source:

 

    September 30,
2026
    September 30,
2025
 
             
System sales    $ 4,720,096      $          11,705,375  
Instruments sale     1,039,939       854,440  
Warranty sale     555,127       244,399  
Lease income     15,899       25,135  
Total revenue    $ 6,331,061      $ 12,829,349  

 

Revenues for the three months ended September 30, 2026 and 2025 by geographic region (determined based upon customer domicile), are as follows:

 

    September 30,
2026
    September 30,
2025
 
             
India    $          6,170,235      $          12,043,038  
South America     97,183       -  
Sri Lanka     36,052       -  
Philippines     10,175       -  
UAE     8,846       8,252  
Nepal     8,570       7,335  
Indonesia     -       131  
Iraq     -       770,593  
     $ 6,331,061      $ 12,829,349  

 

24

 

 

For the nine months ended September 30, 2026 and 2025:

 

The following table disaggregates our revenue by major source:

 

    September 30,
2026
    September 30,
2025
 
             
System sales     $        26,657,452     $         24,988,895  
Instruments sale     3,333,692       2,339,478  
Warranty sale     1,331,815       560,262  
Lease income     49,177       61,629  
Training income     41,825       -  
Total revenue   $ 31,413,961     $ 27,950,264  

 

Revenues for the nine months ended September 30, 2026 and 2025 by geographic region (determined based upon customer domicile), are as follows:

 

    September 30,
2026
    September 30,
2025
 
             
India    $          29,512,002      $          23,796,743  
South America     1,331,431       917,721  
Sri Lanka     423,371       -  
Philippines     71,163       1,409,925  
Indonesia     28,936       1,020,967  
Iraq     -       770,593  
UAE     24,843       22,833  
Nepal     22,215       11,482  
     $ 31,413,961      $ 27,950,264  

 

NOTE 13 – STOCKHOLDERS’ EQUITY

 

Common Stock

 

The Company is authorized to issue up to 250,000,000 shares of common stock, $0.0001 par value per share. The Company has one class of common stock outstanding. Holders of the Company’s common stock are entitled to one vote per share. Upon the liquidation or dissolution of the Company, its common stockholders are entitled to receive a ratable share of the available net assets of the Company after payment of all debts and other liabilities. The Company’s shares of common stock have no pre-emptive, subscription, redemption or conversion rights.

 

As of September 30, 2026, and December 31, 2025, there were 200,488,427 and 194,165,141 common shares issued and outstanding respectively. Holders of common stock are entitled to one vote for each share of common stock.

 

Preferred Stock

 

The Company is authorized to issue up to 5,000,000 shares of preferred stock, $0.0001 par value per share. The Company has one class of preferred stock outstanding “Series A- Preferred Stock”.

 

As of September 30, 2026, and December 31, 2025, there were 1,000 shares of Series A Preferred Stock issued and outstanding.

 

Common Stock issued at the time of Merger

 

At Closing of the Merger on April 14, 2023, 135,808,884 shares of the Company’s common stock and 1,000 shares of the Company’s Series A Preferred Stock were issued to Cardio Ventures. This includes common stock that was issued to Dr. Frederic Moll and one other accredited investor, who each provided $3,000,000 in interim financing to the Company pending consummation of the Merger. Following the Merger an additional 3,818,028 shares of the Company’s common stock were issued to Dr. Frederic Moll per his interim financing agreement with the Company.

 

25

 

 

Common Stock issued post-Merger

 

On February 12, 2025, the Company issued 48,030 shares of common stock to an investor upon against the conversion of note amounting to $213,732 including interest thereon at a conversion price of $4.45 per share.

 

On February 13, 2025, the Company issued 30,010 and 30,008 shares of common stock to two investors, respectively, upon the conversion of notes amounting to $133,546 and $133,534, including interest thereon, respectively at a conversion price of $4.45 per share.

  

On February 20, 2025, the Company issued 16,046,814 shares of common stock to Sushruta Pvt Ltd upon against the conversion of notes amounting to $22,144,603 including interest thereon, at a conversion price of $1.38 per share.

 

On March 1, 2025, the Company issued 7,858 common shares to one ex-employee and 2,619 shares of common stock to an ex-director of the Company upon cashless exercise of stock options previously granted to them under the Company’s 2016 Stock Incentive Plan.

 

On March 31, 2025, the Company issued 5,811,554 shares of common stock to Sushruta Pvt Ltd, upon the conversion of notes amounting to $8,019,945, including interest thereon, at a conversion price of $1.38 per share.

 

On April 2, 2025, the Company issued 3,163 shares of common stock to an advisory firm in accordance with terms of the engagement document signed with them to provide production and graphics services to the Company. 

 

On April 30, 2025, the Company issued 1,639 shares of common stock to an advisor in exchange for rendering services in accordance with the agreement entered with the advisor.

 

On May 22, 2025, the Company issued 20,000 shares of common stock to an advisor in exchange for advisory services to be rendered over a 5-year period. The total value of such services is $196,800. The value of services is calculated at the fair market value of the shares as of the date of the advisory services contract.

 

On May 28, 2025, the Company issued 7,431 shares of common stock to one individual upon the cashless exercise of a stock option previously granted under the Company’s 2016 Stock Incentive Plan.

 

On August 28, 2025, the Company issued 4,000 shares of common stock to an advisor in exchange for advisory services to be rendered over a 5-year period. The total value of such services is $43,560. The value of services is calculated at the fair market value of shares as of the date of the advisory services contract.

 

On October 1, 2025, the Company issued 28,739 shares of common stock to four advisors in exchange for advisory services to be rendered. The shares were issued pursuant to advisory arrangements, and the value of the services was determined based on the fair market value of the Company’s common stock on the date of issuance.

 

On October 22, 2025, the Company issued 16,000 shares of common stock to one individual in exchange for advisory services to be rendered. The total value of such services is $174,200. The value of services is calculated at the fair market value of the Company’s common stock on the date of the advisory services agreement.

 

On November 27, 2025, the Company issued 527,325 shares of common stock to employees pursuant to stock grant awards under the Company’s 2016 Stock Incentive Plan. The stock grants were issued in recognition of employee services, and the related compensation expense was recognized in accordance with applicable accounting guidance.

 

On December 12, 2025, the Company issued 667 shares of common stock to one individual upon the exercise of warrants previously issued by the Company. The warrants were exercised at $2.50 per share in accordance with their terms resulting in net proceeds to the Company of $2,500.

 

On January 9, 2026, the Company issued 191,555 shares of common stock to employees pursuant to stock grant awards under the Company’s 2016 Stock Incentive Plan. The stock grants were issued in recognition of employee services, and the related compensation expense was recognized in accordance with applicable accounting guidance.

 

26

 

 

On March 6, 2026, the Company issued 5,774,839 shares of common stock under a private placement consisting of:

 

● an aggregate of 1,300,006 shares of common stock at an average price of $4.00 per share for a total of $5,197,000 to directors, details of the same are as below:

 

Ø 498,753 shares to Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer at $4.01 per share amounting to $2,000,000;

 

Ø 501,253 shares to Dr. Frederic Moll, our Vice Chairman at $3.99 per share amounting to $2,000,000;

 

Ø 300,000 shares to Tim Adams, a director at $3.99 per share amounting to $1,197,000; and

 

● an aggregate of 4,474,833 shares of common stock at $3.00 per share and total consideration of $13,424,498, to existing and new investors, led by Manipal Global Health Services, an existing shareholder.

 

On June 20, 2026, the Company issued 37,500 shares of its common stock to an individual in connection with a consulting services agreement. The shares were issued as consideration for services to be provided to the Company pursuant to the terms of the agreement.

 

On July 3, 2026, the Company issued 100,000 shares of common stock to an advisor in exchange for advisory services to be rendered over a 5-year period. The total value of such services is $378,000. The value of services is calculated based on the fair market value of the shares as of the date of the advisory services agreement. The shares were fully vested.

 

On August 10, 2026, pursuant to a consulting agreement, the Company issued 116,400 shares of its common stock to a consultant in settlement of the outstanding liability related to services rendered to the Company in prior periods. 

 

On August 19, 2026, the Company issued 22,992 shares of common stock to four advisors in exchange for advisory services. The shares were issued pursuant to advisory arrangements, and the value of the services was determined based on the fair market value of the Company’s common stock on the date of advisory service agreement.

 

On August 19, 2026, the Company issued 70,000 shares of common stock to six advisors in exchange for advisory services to be rendered over a 5-year period. The total value of such services is $261,000. The value of services is calculated based on the fair market value of the shares as of the date of the advisory services agreement. The shares were fully vested.

 

On September 14, 2026, the Company issued 10,000 shares of common stock to an advisor in exchange for advisory services to be rendered over a 5-year period. The total value of such services is $37,800. The value of services is calculated based on the fair market value of the shares as of the date of the advisory services agreement. The shares were fully vested.

 

27

 

 

NOTE 14 – INVENTORY

  

Inventory consists of the following as of:

 

    September 30,
2026
    December 31,
2025
 
             
Raw materials (includes goods in transit $786,135 (December 31, 2025: $502,392)]   $          7,899,103     $          7,027,016  
Work-in-progress     1,171,276       1,426,933  
Finished goods#     13,102,554       8,717,761  
Less: Inventory valuation allowance     (101,720 )     (107,708 )
    $ 22,071,213     $ 17,064,002  

 

# Including two systems of $487,316 and nil as of September 30, 2026 and December 31, 2025, respectively, located at distributor on behalf of the Company for the purposes of FDA clinical trials.

 

Changes in the inventory valuation allowance for the three and nine months ended September 30, 2026 is as follows:

 

    For the three months period ended  
    September 30,
2026
    September 30,
2025
 
             
Balance at the beginning of the year   $          101,634                                     -  
Additions / (Reversals)     -       -  
Foreign currency translation adjustment     86       -  
Balance at the end of the year   $ 101,720       -  

 

    For the nine months period ended  
    September 30,
2026
    September 30,
2025
 
             
Balance at the beginning of the year   $               107,708                               -  
Additions / (Reversals)     (6,179 )     -  
Foreign currency translation adjustment     191       -  
Balance at the end of the year   $ 101,720       -  

 

The provision for slow-moving and obsolete inventory is recognized within cost of sales in the Consolidated Statements of Operations.

 

28

 

 

NOTE 15 – LEASES

 

The Company conducts its operations using facilities leased under operating lease agreements that expire at various dates.

 

The following is a summary of operating lease assets and liabilities as of:

 

Operating leases   September 30,
2026
    December 31,
2025
 
Assets            
Right of use operating lease assets   $         2,825,720     $         2,754,020  
                 
Liabilities                
Current portion of operating lease liabilities     705,711       579,169  
Non-Current portion of operating lease liabilities     2,326,354       2,337,697  
Total lease liabilities   $ 3,032,065     $ 2,916,866  

 

Operating leases   September 30,
2026
    December 31,
2025
 
Weighted average remaining lease terms (years)            
Ilabs Info Technology 3rd Floor                      3.44                       4.19  
Ilabs Info Technology 1st Floor     3.83       4.58  
Ilabs Info Technology Ground Floor     5.67       6.42  
Ilabs Info Technology Basement-3     3.44       4.19  
Ilabs Info Technology 7th Floor     4.83       -  
Village Chhatarpur-1849-1852-Farm     1.00       1.75  
                 
Weighted average discount rate                
Ilabs Info Technology 3rd Floor     12.00 %     12.00 %
Ilabs Info Technology 1st Floor     12.00 %     12.00 %
Ilabs Info Technology Ground Floor     12.00 %     12.00 %
Ilabs Info Technology Basement-3     12.00 %     12.00 %
Ilabs Info Technology 7th Floor     12.00 %     -  
Village Chhatarpur-1849-1852-Farm     10.00 %     10.00 %

 

Supplemental cash flow and other information related to leases are as follows:

 

    Period ended  
    September 30,
2026
    September 30,
2025
 
Cash payments for amounts included in the measurement of lease liabilities:            
Operating cash outflows for operating leases                677,535                  573,363  

 

29

 

 

Maturities of lease liabilities as of September 30, 2026 are as follows:

 

Fiscal year   Operating
Leases Amount
 
2026, excluding the nine months ended September 30, 2026   $ 251,673  
2027     968,368  
2028     823,867  
2029     859,362  
2030     539,650  
2031 and thereafter     433,896  
Total lease payment     3,876,816  
Less: Imputed Interest     844,751  
Present value of lease liabilities   $ 3,032,065  

 

NOTE 16 – INCOME TAX

 

The effective tax rate for the three months ended September 30, 2026 was 3.43%, compared to (98.73%) for the three months ended September 30, 2025. The Company recorded income tax expense of $(204,259) and $1,847,059 for the three months ended September 30, 2026 and 2025, respectively. The decrease in income tax expense during the current period was primarily attributable to taxable losses generated by the Company’s Indian operations. Income tax expense recognized in the corresponding prior-year period was comparatively higher due to higher taxable profits generated by the Indian operations.

 

The effective tax rate for the nine months ended September 30, 2026 was (3.91%), compared to (29.52%) for the nine months ended September 30, 2025. The Company recorded income tax expense of $452,369 and $2,200,788 for the nine months ended September 30, 2026 and 2025, respectively. The decrease in income tax expense during the current period was primarily attributable to lower taxable income generated by the Company’s Indian operations. Income tax expense recognized in the corresponding prior-year period was comparatively higher due to higher taxable profits generated by the Indian operations.

 

Deferred income tax benefit / (expense) is recognized in OCI as follows:

 

    For the three months ended     For the nine months ended  
    September 30,
2026
    September 30,
2025
    September 30,
2026
    September 30,
2025
 
Particulars                        
Domestic                        
Federal   $ -     $ -     $ -     $ -  
State     -       -       -       -  
Foreign                                
India                                
Retirement benefits     (1,688 )     (646 )     3,564       5,126  
Total   $             (1,688 )   $                 (646 )   $               3,564     $               5,126  

 

As of September 30, 2026, and December 31, 2025, the Company recorded a valuation allowance of $16,708,511 and $12,870,003, respectively, against deferred tax assets arising from net operating losses and temporary differences in its U.S. operations, due to a history of operating losses and limited visibility into future taxable income. Based on the assessment, deferred tax assets related to the Indian operations are considered realizable, and no valuation allowance has been recorded for those jurisdictions.

 

The Company’s policy is to recognize interest and penalties related to uncertain income tax matters within income tax expense in the condensed consolidated statements of operations. As of September 30, 2026 and December 31, 2025, the Company had accrued $565,750 and $525,278 respectively, related to income-tax-related interest.

 

As of September 30, 2026, the Company has no unrecognized tax benefits. 

 

30

 

 

NOTE 17 – EMPLOYEE BENEFIT PLAN

 

The Company’s Gratuity Plan in India provides for a lump sum payment to vested employees on retirement or upon termination of employment in an amount based on the respective employee’s salary and years of employment with the Company. Liabilities under this plan are determined by actuarial valuation using the projected unit credit method. Current service costs for these plans are accrued in the year to which they relate. Actuarial gains or losses or prior service costs, if any, resulting from amendments to the plans, are recognized and amortized over the remaining period of service of the employees.

 

The Gratuity Plan is unfunded, and the Company does not make contributions to the plan assets.

 

The benefit obligation has been measured as of September 30, 2026, and December 31, 2025. The following table sets forth the activity and the amounts recognized in the Company’s consolidated financial statements at the end of the relevant periods:

 

    September 30,
2026
    December 31,
2025
 
Change in projected benefit obligation            
Projected benefit obligation at beginning   $ 208,571     $ 80,833  
Service cost     64,465       59,280  
Amortization of prior service cost     9,067       1,433  
Interest cost     11,161       5,627  
Benefits paid     -       -  
Actuarial (gain) / loss ^     14,162       29,553  
Prior service cost     -       37,823  
Effect of exchange rate changes     (24,848 )     (5,978 )
Projected benefit obligation at end     282,578       208,571  
Unfunded status in the end     282,578       208,571  
Unfunded amount recognized in consolidated balance sheets                
Non-current liability (included under other non-current liabilities)     252,630       188,622  
Current liability (included under accrued employee costs)     29,948       19,949  
Total accrued liability     282,578       208,571  
Accumulated benefit obligation at end   $ 142,649     $ 101,031  

 

^ During the nine months period ended September 30, 2026, and December 31, 2025, actuarial loss was driven by changes in actuarial assumptions, offset by experience adjustments on present value of benefit obligations.

 

Components of net periodic benefit costs recognized in condensed consolidated statements of operations and comprehensive loss and actuarial loss reclassified from AOCI, are as follows:

 

    September 30,
2026
    September 30,
2025
 
             
Service cost   $ 64,465     $ 35,102  
Amortization of prior service cost     9,067       -  
Interest cost     11,161       4,244  
Net gratuity cost   $ 84,693     $ 39,346  

 

31

 

 

The components of retirement benefits included in AOCI, excluding tax effects, are as follows:

 

    September 30,
2026
    September 30,
2025
 
             
Net actuarial loss   $ 14,162     $ 20,366  
Amount recognized in AOCI, excluding tax effects   $ 14,162     $ 20,366  

 

The weighted average actuarial assumptions used to determine benefit obligations and net gratuity cost are as follows:

 

    September 30,
2026
    September 30,
2025
 
             
Discount rate     7.82 %     7.38 %
Rate of increase in compensation levels     15.50 %     12.50 %

 

The Company evaluates these assumptions annually based on its long-term plans of growth and industry standards. The discount rates are either based on current market yields on government securities or yields on government securities adjusted for a suitable risk premium, if available

 

Expected benefit payments as of September 30, 2026 are as follows:

 

2026, excluding the nine months ended September 30, 2026   $ 29,948  
2027     56,217  
2028     51,556  
2029     47,788  
2030     36,774  
2031-2035   $ 193,791  

 

NOTE 18 – FAIR VALUE MEASUREMENT – FINANCIAL INSTRUMENTS

 

Assets and liabilities recorded at fair value are measured using the fair value hierarchy, which prioritizes the inputs used in measuring fair value. The levels of the fair value hierarchy are:

 

  ● Level 1: observable inputs such as quoted prices in active markets.

 

  ● Level 2: inputs other than quoted prices in active markets that are either directly or indirectly observable; and

 

  ● Level 3: unobservable inputs for which little or no market data exists, therefore requiring the Company to develop its own assumptions.

 

The Company’s financial assets which are set out below in the table are measured at fair value by considering the level III inputs. The company does not have financial assets which are measured using Level I or Level II inputs.

 

32

 

 

Carrying value and fair value of Level III Financial assets and liabilities are as follows:

 

    Carrying Value     Fair Value  
    September 30,
2026
    December 31,
2025
    September 30,
2026
    December 31,
2025
 
                         
Financial Assets                        
Account receivables, net (1)   $ 7,314,087     $ 8,566,654     $ 7,314,087     $ 8,566,654  
Lease receivables (2)     2,369,943       1,410,589       2,369,943       1,410,589  
Other non-current financial assets (3)     245,880       248,027       245,880       248,027  
Total     9,929,910       10,225,270       9,929,910       10,225,270  
Financial Liabilities                                
Lease liabilities (3)     2,326,354       2,337,697       2,326,354       2,337,697  
Total   $ 2,326,354     $ 2,337,697     $ 2,326,354     $ 2,337,697  

 

(1) Account receivable net of allowance represents the long-term debtors of the company in relation to the sales made during the year. The Company has presented the receivable balances account after reducing the significant financing component included using the discount rate of 10%.

 

(2) Lease receivables arising from sales-type leases are measured which is based on a discounted cash flow methodology that incorporates significant unobservable inputs, including assumptions related to discount rate, expected timing of cash flows etc. (Refer to Note 5).

 

(3) Other non-current assets include security deposits and long-term fixed deposits with banks. Company has calculated the fair value of security deposit at present value of future receipt using discount rate of 7% and fair value of long-term fixed deposit with banks are carried at cost which is approximate to the fair value.

 

(4) The Company has long-term lease liabilities in relation to office properties which is carried at cost using the discount rate (Refer Note to 15 Lease).

 

NOTE 19 – STOCK-BASED COMPENSATION EXPENSES

 

Stock options to Employees: The Company grants shares of the Company’s common stock, par value $ 0.0001 to certain employees under the Company’s 2016 Stock Incentive Plan (the “Plan”). The price at which the Grantee is entitled to purchase the Shares upon the exercise of the Option (the “Option Price”) is $ 5.00 per Share. The Shares vest twenty percent (20%) as of the Grant Date, with the balance of the shares vesting in four equal annual installments on the first, second, third and fourth anniversaries of the Grant Date provided that the Grantee remains in the Continuous Employment of the Company or any of its subsidiaries or affiliates, as defined and provided for in the 2016 Stock Incentive Plan. The Options, to the extent vested and not exercised, shall expire five (5) years from the Grant Date.

 

Restricted Stock Award to Employees: The Company grants restricted shares of the Company’s common stock, $ 0.0001 per value to certain employees under the Plan. The grant of restricted shares is made in consideration of services to be rendered by the Grantee to the Company. The Restricted Stock Awards vest twenty percent (20%) as of the Grant Date, with the balance of the Restricted Shares vesting in four equal annual installments on the first, second, third and fourth anniversaries of the Grant Date, subject to the Grantee’s continued employment by the Company, as provided for in the Plan. Unvested portions of the Restricted Stock Award may not be transferred at any time, except to the extent provided for in the Plan. Until the Restricted Stock Award granted under this Agreement vests in accordance with the terms hereof, the Grantee shall have no rights as a stockholder (including, without limitation, voting and dividend rights) with respect to any of the Restricted Shares covered by the Restricted Stock Award.

 

Stock Awards issued to Doctors/Proctors/Advisors (“Advisor’s”): The Company issues shares of the Company’s common stock (“Advisory Shares”) to retain and compensate certain Advisors for performing services for the Company and in exchange for the compensation, which is issued in a phased manner as determined by the company. The “Services” include but are not limited to (a) providing proctoring and medical advisory services, (b) advising the Company on the development of surgical robotics procedures and improvements in design and technology (c) participation in case of observation and performance of live surgeries, and (d) disseminating information about the Company’s products in various scientific meetings and surgical robotic conferences globally (e) investor’s digital marketing support. The Company issues such Advisory Shares in a phased manner commensurate with the period over which the services are to be performed, as determined by the Company.

 

33

 

 

Stock options

 

Stock options activity for the period ended September 30, 2026, is as follows:

 

    Number of
shares
options
    Weighted
average grant date fair value
per share
 
             
Unvested balance as of December 31, 2025     1,691,184     $ 3.41  
Granted     -       -  
Vested     -       -  
Forfeited     -       -  
Unvested balance as of September 30, 2026     1,691,184     $ 3.41  

 

    Number of
shares
options
    Weighted
average grant
date fair value
per share
 
                 
Exercisable balance as of September 30, 2026     5,886,997     $ 2.26  

 

During the nine months ended September 30, 2026, no stock options vested. Further there were no stock options granted during the nine months ended September 30, 2026. 

 

Restricted Stock Awards (“RSAs”)

 

RSA activity for the nine months ended September 30, 2026, is as follows:

 

    Number of
shares
RSAs
    Weighted
average grant
date fair value
per share
 
             
Unvested balance as of December 31, 2025     1,054,638     $ 7.76  
Granted     957,797     $ 5.52  
Vested     191,555     $ 5.52  
Forfeited     215,458     $ 6.95  
Unvested balance as of September 30, 2026     1,605,422     $ 6.80  

 

      Number of
shares
RSAs
      Weighted
average grant
date fair value
per share
 
                 
Exercisable balance as of September 30, 2026     -       -  

 

 

34

 

 

During the period ended September 30, 2026, 191,555 RSAs vested and were issued to the grantee.

 

Advisory shares

 

Common stock issued to consultants as advisory shares for the nine months ended September 30, 2026 is follows:

 

Grant dates   Fair
value
on grant
date
    Unvested
shares
in the
beginning
    Shares
granted
during the
year
    Shares
vested
during the
period
    Unvested
shares
at the end
of the
period
 
31-Oct-23     8.99       34,541       -       10,362       24,179  
31-Oct-23     8.99       4,650       -       1,395       3,255  
31-Oct-23     8.99       3,700       -       1,110       2,590  
31-Oct-23     8.99       14,588       -       4,376       10,212  
2-Jul-26     3.78       -       100,000       100,000       -  
3-Jul-26     3.78       -       20,000       20,000       -  
3-Jul-26     3.78       -       10,000       10,000       -  
16-Jul-26     3.61       -       20,000       10,000       10,000  
16-Jul-26     3.61       -       20,000       10,000       10,000  
23-Jul-26     3.57       -       20,000       10,000       10,000  
4-Aug-26     3.83       -       20,000       10,000       10,000  
10-Aug-26     3.75       -       20,000       10,000       10,000  
              57,479       230,000       197,243       90,236  

 

The aggregate vesting date fair value of Advisory shares vested was $830,121 and $498,496 during the period ended September 30, 2026 and year ended December 31, 2025, respectively.

 

Stock-based compensation expenses

 

During the period ended September 30, 2026 and September 30, 2025, the Company recorded share-based compensation expense of $7,476,455 in relation to stock options, RSU and Advisory shares as follows:

 

    September 30,
2026
    September 30,
2025
 
Stock options   $ 2,156,676     $ 2,156,676  
Restricted stock units (RSU)     4,358,515       2,986,730  
Advisory shares     961,264       961,264  
Total stock-based compensation expenses   $ 7,476,455     $ 6,104,670  

 

35

 

 

Stock option model and assumptions

 

The Black-Scholes-Merton option pricing model is used to estimate the fair value of stock options and RSU granted under the Company’s share based compensation plans and the rights to acquire stock granted under the stock options plans. The weighted-average estimated fair values of stock options and the rights to acquire stock as well as the weighted-average assumptions used in calculating the fair values of stock options and the rights to acquire stock that were granted till September 30, 2026 is as follows:

 

    Nine months ended September 30, 2026  
Grant date   Restricted
stock awards
January 09,
2026
    Stock Options
February 13,
2024
    Stock Options
November 27,
2023
    Restricted
stock awards
November 27,
2023
 
                         
Fair value on grant date   $ 5.52     $ 1.39     $ 3.41     $ 7.76  
Risk free interest rate     4.40 %     4.40 %     4.40 %     4.40 %
Expected volatility     18.29 %     24.96 %     18.50 %     18.50 %
Exercise prices   $ 0.0001     $ 5.00     $ 5.00     $ 0.0001  
Share price on the grant date   $ 5.52     $ 5.50     $ 7.76     $ 7.76  
Expected term of vesting     4 years       2.5 years       4 years       4 years  

 

As share-based compensation expense recognized in the Condensed Consolidated Statements of operations and comprehensive loss during the period ended September 30 2026, and 2025, is based on awards ultimately expected to vest, and has been reduced for estimated forfeitures, if any.

 

As of September 30, 2026, there was $3,333,763, $7,285,656 of total unrecognized compensation expense related to unvested stock options and restricted stock units to acquire common stock under the 2016 Stock Inventive Plan respectively. The unrecognized compensation expense is expected to be recognized over a weighted-average period of 2.22 years for unvested stock options and restricted stock units for rights granted to acquire common stock under 2016 Incentive Stock Plan.

 

36

 

 

NOTE 20 – RELATED PARTY TRANSACTIONS

 

The details of transactions with the related parties for the nine months ended September 30, 2026 and 2025 and balances outstanding as on September 30, 2026 and December 31, 2025 are as follows:

 

Particulars   For the period ended September 30, 2026     For the period ended September 30, 2025  
Transactions during the year:            
Particular   Amount     Amount  
             
Expenses incurred on behalf of affiliates            
Srivastava Robotic Surgery Pvt Ltd   $ 330     $ 53  
SS International Centre For Robotics Surgery Pvt Ltd*     -       12,897  
Sudhir Srivastava Medical Innovations Pvt Ltd     407       71  
Telegnosis Pvt Ltd     70       218  
Sudhir Prem Srivastava, M.D.     -       18,000  
                 
Expense incurred on behalf of Company                
Sudhir Prem Srivastava, M.D.     73,903       136,572  
Barry F. Cohen     -       5,753  
Dr. Frederic H Moll     -       11,499  
Milan Rao#     4,216       -  
Dr. S.P. Somashekhar     510       5,574  
Mr. Tim Adams     1,867       -  
Vishwajyoti P. Srivastava, M.D.     2,800       -  
                 
2016 Stock Incentive Plans Expenses/(Reversal)                
Anup Sethi     -       (122,247 )
Barry F. Cohen     431,335       431,335  
Dr. S.P. Somashekhar     159,295       158,190  
Sudhir Prem Srivastava, M.D.     1,294,006       1,294,006  
Vishwajyoti P. Srivastava, M.D.     431,335       431,335  
Milan Rao#     170,150       -  
Dr Manjiri Somashekhar     1,580       -  
                 
Loan from Related Parties                
Sudhir Prem Srivastava, M.D.     215,218       -  
                 
Consultancy charges and other perquisites                
Anup Sethi     -       65,738  
Barry F. Cohen     135,000       135,000  
Sudhir Prem Srivastava, M.D.     719,492       664,586  
Vishwajyoti P. Srivastava, M.D.     293,997       225,510  
Arvind Palaniappan#     -       16,202  
Milan Rao#     140,002       -  
Dr. Frederic H Moll     7,500       -  
Dr. S.P. Somashekhar     7,500       -  
Mr. Tim Adams     7,500       -  
Mylswamy Annadurai     6,000       -  
Naveen Kumar Amar#     -       3,080  
Sarah M. Romano#     22,473       -  
                 
Proceeds from Private Investment in Public Equity                
Sushruta Private Limited     2,000,000       -  
Mr. Tim Adams     1,197,000       -  
Dr. Frederic H Moll     2,000,000       -  
                 
Proceeds from notes issued                
Sushruta Private Limited     -       28,000,000  
                 
Interest accrued on notes                
Sushruta Private Limited     -       182,400  
                 
Conversion of notes into common stock                
Sushruta Private Limited   $ -     $ 30,164,548  

 

37

 

 

Balance outstanding as of period end:

 

Accrued expenses & other current liabilities:   As of
September 30,
2026
    As of
December 31,
2025
 
Balance receivable / (payable)            
Barry F. Cohen   $ (595,500 )   $ (496,253 )
Sarah M. Romano#     (22,473 )     -  
                 
Prepaids and other current assets:                
Srivastava Robotic Surgery Pvt Ltd     689       394  
SS International Centre For Robotics Surgery Pvt Ltd*     -       17,360  
Cardio Bahamas^     (76,741 )     (76,741 )
SSI PTE Singapore^     (424,586 )     (424,586 )
Sudhir Prem Srivastava, M.D.^     1,886,788       2,378,493  
Sudhir Srivastava Medical Innovations Pvt Ltd     915       556  
Telegnosis Private Limited     1,246       1,257  
Sushruta Private Limited     5,000       5,000  
Vishwajyoti P. Srivastava, M.D.   $ -     $ 10,178  

 

^ For these balances, Dr. Sudhir Prem Srivastava is considered as the ultimate beneficial owner, and the settlement is expected to be made on net basis. Accordingly, these balances have been disclosed under prepaids and other current assets.

 

# Mr. Naveen Kumar Amar resigned from the position of Chief Financial Officer effective January 2, 2026. Thereafter, on January 16, 2026, the Company appointed Milan Rao as Global Chief Operating Officer and Chief Financial Officer. Mr. Milan Rao subsequently resigned from his position as Chief Financial Officer, effective May 25, 2026. Subsequently, on August 3, 2026, the Company appointed Sarah M. Romano as Chief Financial Officer. Sarah M. Romano subsequently resigned from her position as Chief Financial Officer, effective August 21, 2026 and Dr. Sudhir Srivastava has served as Interim Chief Financial Officer since August 22, 2026.

 

* Refer to Note 1.

 

NOTE 21 – COMMITMENTS AND CONTINGENCIES

 

Capital Commitments 

 

As of September 30, 2026, the Company has capital commitments of $66,003 (net of advances nil), primarily related to the construction of leasehold improvements for rental office premises. These commitments are expected to be incurred over 1 to 2 months and will be funded through the Company’s existing cash and cash equivalents and cash generated from operations.

 

The commitments are subject to the terms of the underlying purchase orders and contracts, including customary provisions that may permit modification or cancellation. No liability has been recognized for amounts related to goods or services not received as of September 30, 2026.

 

Other Commitments

 

The Company, through its SSI-India subsidiary, occupies office, manufacturing, and assembly space in Gurugram, Haryana (India) under a lease agreement entered into in March 2021, with monthly payments of $23,670 plus applicable taxes. This lease expires in March 2030. Effective June 01, 2023, SSI-India subsidiary signed another lease agreement for occupying an additional space in Gurugram, to further expand its manufacturing and assembly capacity. This lease provides for a monthly payment of $15,639 plus taxes and expires on May 31, 2032, subject to further renewal on mutually acceptable terms. Further effective from August 1, 2024 SSI-India subsidiary signed another lease agreement for occupying an additional space in Gurugram, to further expand its operations. This lease provides for a monthly payment of $8,411 plus taxes and expires on July 31, 2030. In May 2025, the Company signed another lease agreement for occupying an additional space for warehouse purposes in Gurugram which provides for monthly payment of $3,391 plus taxes and expires in March 2030. Further effective from May 1, 2026, the Company executed a lease agreement for an additional floor after renegotiating the commercial terms of the proposed arrangement. This lease provides for a monthly payment of $14,363, plus taxes and expires in July 2031. SSI-India leased a residential property to provide residential accommodation. This lease provides for a monthly payment of $20,456 plus taxes.

 

38

 

 

Contingencies

 

SSI-India the Company’s Indian operating subsidiary, has received the draft assessment order dated November 29, 2023 under section 144C(1) related to proposed transfer pricing adjustment of $510,242 to the returned income for the assessment year 2021-22, primarily on account of Rejection of the segmental margins computed by the Company and adoption of entity-level margins; and Modification of the filters applied by the Company in the selection of comparable companies.

 

Further, the Company had filed its objections before the Dispute Resolution Panel (DRP). The DRP, vide its directions dated August 28, 2024, granted partial relief of $16,064 on account of rectification in the operating margins of the comparable companies. Accordingly, the Transfer Pricing adjustment was reduced to $494,178. Subsequently, the Company has filed an appeal before the Income Tax Appellate Tribunal (ITAT) on the remaining disputed issues and the said case is pending for hearing before the ITAT. The Management believes that its position will more likely than not be sustained upon final examination by the tax authorities and accordingly has not accrued any liabilities with respect to this matter in its consolidated financial statements.

 

Subsequently, the Company has filed an appeal before the Income Tax Appellate Tribunal (ITAT) on the remaining disputed issues. As informed by the Management, the matter is pending adjudication before the ITAT. The Company believes that its position will more likely than not be sustained upon final examination by the tax authorities and accordingly has not accrued any liabilities with respect to these matters in its consolidated financial statements.

 

NOTE 22 – SUBSEQUENT EVENTS

 

On October 9, 2026, the Company completed a financing transaction in a private offering with an institutional investor pursuant to which it received gross proceeds of $20,000,000. In the financing, the Company issued a secured convertible promissory note to Growth Capital Partners, LLC, a Utah limited liability company, for principal amounting to $21,025,000 at a purchase price of $20,000,000. This note carries an original issue discount of $1,000,000. In addition, the Company agreed to pay $25,000 to the investor (Growth Capital Partners, LLC) to cover the investor’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of the note. The note bears interest at 8.75% per annum, compounded daily, matures 36 months from issuance, is convertible into common stock at 95% of the Market Price (as defined in the note), and is subject to monthly investor redemptions beginning 12 months after issuance, payable in cash or shares. The note is secured by the Company’s intellectual property and the assets of the Company and its intellectual property holding subsidiary, SSI IP Holdings, Inc., excluding the assets and capital stock of SSI-India, the Company’s Indian operating subsidiary.

 

SSi intends to use the net proceeds from this financing transaction for working capital and other general corporate purposes, which include, but are not limited to advancing the Company’s growth initiatives in India and other existing global markets and supporting preparation for entry into the United States and European Union markets.

 

On October 20, 2026, the Company issued 7,369 common shares to one ex-employee and 1,842 common shares to an ex-director of the Company on cash-less conversion of the options held by them as per the terms of the Stock Option Agreement options executed by them with the Company.

 

On October 20, 2026, the Company issued 35,000 shares of common stock to one individual upon the exercise of warrants previously issued by the Company. The warrants were exercised at $2.50 per share in accordance with their terms resulting in net proceeds to the Company of $87,500.

 

On October 20, 2026, the Company issued 1,732 shares of its common stock to an individual in connection with a consulting services agreement. The shares were issued as consideration for services to be provided to the Company pursuant to the terms of the agreement.

 

On November 4, 2026, the Company issued 10,000 shares of its common stock to an advisor pursuant to the terms of an advisory agreement. The shares were issued as compensation in exchange for advisory services to be performed for the Company under the terms of the agreement.

 

On November 9, 2026, the Company issued 33,623 shares of its common stock to, Growth Capital Partners, LLC against its rights under the Limited Redemption provision of the financing agreement with the Company, resulting in the redemption of $50,000 of the outstanding balance.

 

Effective, November 6, 2026, the Company appointed Gary G. Lo as its Chief Financial Officer.

 

39

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Introduction

 

We are engaged in the business of developing, manufacturing, and selling a surgical robotic system under its proprietary brand “SSi Mantra,” together with allied accessories and a wide range of surgical instruments capable of supporting cardiac and a variety of other surgical procedures under its proprietary brand “SSi Mudra”. Having commenced commercial sales of our surgical robotic system in the second half of 2022, the year 2023 was our first full year of commercial sales and during the year 2024, we introduced our upgraded SSi Mantra 3 system, further consolidated our installed base of SSi Mantra in various parts of India and began to expand our presence in other global markets. Those efforts continued during 2025 with filing for U.S. FDA approval and EU CE mark approval during the year ended December 31, 2025, and are ongoing in 2026. We are also undertaking development efforts to expand our product line in connection with our goal to make robotic surgery more affordable and accessible.

 

Our financial performance is largely driven by increasing awareness of the benefits of robotically assisted surgery, reduced learning curves for robotic surgeons and the affordability and accessibility of surgical robotic technology. Our financial performance is also dependent on our obtaining regulatory approvals in various regulated markets where we plan to sell our products. Robotically assisted surgeries are increasingly being recognized as an approved treatment modality from an insurance coverage perspective.

 

Our manufacturing operations being based in India derive significant operating cost advantages in terms of availability of quality and cost-effective fabrication/3D printing solutions, electronic/electrical/mechanical components, outsourced services and skilled manpower. All these factors help achieve lower costs of production and make our surgical robotic system cost effective and relatively affordable.

 

During the nine months ended September 30, 2026, the Company sold 54 SSi Mantra surgical robotic systems, installed 8 systems under a pay-per-use arrangement (including sale type leases), installed 1 system for demonstration purposes, and upgraded 3 previously installed systems.

 

Results of Operations

 

Introduction

 

The financial statements appearing elsewhere in this report have been prepared assuming that we will continue as a going concern. We are still in our initial years of revenue generation by way of the sale of our product and have not yet established consistent operational revenue cash flows to meet all its fixed operating costs and hence may continue to incur losses for some time. These conditions raise substantial doubt about our ability to continue as a going concern.

 

Balance Sheet Data 

 

   September 30,
2026
   December 31,
2025
 
Cash and cash equivalents  $8,113,767   $3,206,406 
Restricted cash   10,491,166    6,396,614 
Total Assets      96,507,411      74,226,217 
Total Liabilities   46,566,800    36,007,966 
Total stockholders’ equity  $49,940,611   $38,218,251 

 

** Represents Fixed Deposits held by bank as security for bank facilities and certain performance guarantees.

 

To date, we have mainly relied on debt and equity raised in private and public offerings to finance its operations. During the balance of the year ending December 31, 2026, we plan to raise additional capital through further private or public offerings of our securities. However, if we are unable to do so and if we experience a shortfall in operating capital, we could be faced with having to limit our expansion plans, research and development efforts and marketing activities.

 

On June 18, 2026, we entered into an ATM Sales Agreement with Virtu Americas LLC, as sales agent, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time in “at the market” offerings pursuant to our shelf registration statement on Form S-3 (File No. 333-295501). Virtu is entitled to compensation of up to 3.0% of the gross proceeds of any shares sold. As of September 30, 2026, we had not sold any shares under the ATM Sales Agreement.

 

On October 9, 2026, the Company completed a financing transaction in a private offering with an institutional investor pursuant to which it received gross proceeds of $20,000,000. In the financing, the Company issued a secured convertible promissory note to Growth Capital Partners, LLC, a Utah limited liability company, for principal amounting to $21,025,000 at a purchase price of $20,000,000. This note carries an original issue discount of $1,000,000. In addition, the Company agreed to pay $25,000 to the investor (Growth Capital Partners, LLC) to cover the investor’s legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale of the note. The note bears interest at 8.75% per annum, compounded daily, matures 36 months from issuance, is convertible into common stock at 95% of the Market Price (as defined in the note), and is subject to monthly investor redemptions beginning 12 months after issuance, payable in cash or shares. The note is secured by the Company’s intellectual property and the assets of the Company and its intellectual property holding subsidiary, SSI IP Holdings, Inc., excluding the assets and capital stock of SSI-India, the Company’s Indian operating subsidiary.

 

40

 

 

SSi intends to use the net proceeds from this financing transaction for working capital and other general corporate purposes, which include, but are not limited to advancing the Company’s growth initiatives in India and other existing global markets and supporting preparation for entry into the United States and European Union markets.

 

Three months ended September 30, 2026, as compared to the three months ended September 30, 2025

 

   For the three months ended 
Particulars  September 30,
2026
   September 30,
2025
 
Total Revenue  $6,331,061   $12,829,349 
Cost of revenue   (3,223,059)   (6,664,413)
Gross profit   3,108,002    6,164,936 
Research & development expense   2,500,826    786,319 
Stock compensation expense   2,153,984    2,095,163 
Depreciation and amortization expense   359,249    297,173 
Selling, general and administrative expense   4,150,363    4,821,552 
Loss from operations   (6,056,420)   (1,835,271)
Other income (expenses)   102,772    (35,634)
Income tax expense   (204,259)   1,847,059 
Net loss  $(5,749,389)  $(3,717,964)

 

Total Revenue. For the three months ended September 30, 2026, we had revenues of $6,331,061 (comprised of $4,720,096 of system sales, $1,039,939 of instrument sales, $555,127 of warranty sales and lease income $15,899), compared to revenues of $12,829,349 (comprising $11,705,375 of system sales, $854,440 of instrument sales, $244,399 of warranty sales and lease income $25,135), during the three months ended September 30, 2025. The decrease in revenue is primarily due to a decrease in the number of SSi Mantra 3 surgical robotic systems and instruments sold during the three months ended September 30, 2026, as compared to the three months ended September 30, 2025. The decrease was due in part from increased emphasis placed on multi-system sales to multiple hospital operators and government health agencies, which generally require a longer timeline to negotiate and consummate.

 

Research and Development Expenses. Research and development expenses for the three months ended September 30, 2026, were $2,500,826, as compared to $786,319 for the three months ended September 30, 2025. The increase was primarily attributable to higher expenditures incurred in connection with clinical trials and related regulatory activities undertaken to support the Company’s efforts to obtain regulatory approvals, including U.S. Food and Drug Administration (the “FDA”) approval to market and CE Mark certification in the European Union.. The increase also reflects higher professional service fees associated with these regulatory initiatives, including regulatory consulting, clinical trial management, testing, documentation, and other compliance-related activities. In contrast, research and development activities during the prior-year period were primarily focused on routine product enhancements, which required relatively lower levels of expenditure.

 

Stock-based compensation expense. We had stock-based compensation expenses of $2,153,984 and $2,095,163 during the three months ended September 30, 2026 and 2025, respectively. The increase in stock-based compensation expense was primarily attributable to the issuance of new Restricted Share Awards, as well the vesting of advisory shares during the current period, under our 2016 Stock Incentive Plan.

 

Depreciation and amortization expense. We had depreciation and amortization expense of $359,249 for three months ended September 30, 2026, as compared to $297,173 for three months ended September 30, 2025. The increase in depreciation and amortization expense was primarily attributable to an increase in fixed assets during the current period.

 

Selling, general and administrative expense. We incurred $4,150,363 in selling, general and administrative (“SG&A”) expense during the three months ended September 30, 2026, as compared to $4,821,552 for the three months ended September 30, 2025.

 

41

 

 

Our SG&A expense is comprised of expenses relating to salaries and benefits, retirement benefits as well as costs related to recruitment, other compensation expenses of sales and marketing and client management personnel, sales commission, travel and brand building, client events and conferences, training and retention of senior management and other support personnel in enabling functions, telecommunications, utilities, travel and other miscellaneous administrative costs. SG&A expenses also include legal and professional fees (which represent the costs of third party legal, tax, accounting, immigration and other advisors), investment in product development, digital technology, advanced automation and robotics, related to grants of our equity awards to members of our board of directors. The decrease in SG&A expenses compared to the prior-year period was primarily attributable to one-time professional fees incurred in connection with the public offering during the prior-year period.

 

Other income, net. We have recognized $102,772 in interest income (net) for the three months ended September 30, 2026, as compared to ($35,634) during the three months ended September 30, 2025. The increase in net income was mainly due to increase in interest income from sales and fixed deposits, partially offset by increase in interest expense incurred on borrowings.

 

Income tax expense. For the three months ended September 30, 2026, income tax expense was ($204,259) as compared to $1,847,059 for the three months ended September 30, 2025, The decrease is primarily due to decrease in the taxable profits arising from the Indian operations as compared to previous period resulting in decrease of income tax expense, majorly due to reduction in system sales.

 

Net Loss. We incurred net loss of $5,749,389 for the three months ended September 30, 2026, as compared to a net loss of $3,717,964 for the three months ended September 30, 2025. The increase in net loss for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 is primarily the result of an increase in research & development expense of $1,714,507, stock-based compensation expense of $58,821, depreciation and amortization expense of $62,076 and decrease in gross profit of $3,056,934 offset by decrease in SG&A expense and income tax expense amounting to $671,189 and $2,051,318, respectively as compared to the prior-year period.

 

Nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025

 

   For the nine month ended 
Particulars  September 30,
2026
   September 30,
2025
 
Total Revenue  $31,413,961   $27,950,264 
Cost of revenue   (15,835,963)   (14,783,062)
Gross profit   15,577,998    13,167,202 
Research & development expense   5,891,960    2,295,014 
Stock compensation expense   7,476,455    6,104,670 
Depreciation and amortization expense   1,029,360    766,416 
Selling, general and administrative expense   13,165,885    11,460,139 
Loss from operations   (11,985,662)   (7,459,037)
Other income (expenses)   412,411    3,817 
Income tax expense   452,369    2,200,788 
Net loss  $(12,025,620)  $(9,656,008)

 

Total Revenue. For the nine months ended September 30, 2026, we had revenues of $31,413,961 (comprised of $26,657,452 of system sales, $3,333,692 of instrument sales, $1,331,815 of warranty sales, $49,177 of lease income and training income $41,825), compared to revenues of $27,950,264 (comprising $24,988,895 of system sales, $2,339,478 of instrument sales, $560,262 of warranty sales and lease income $61,629), during the nine months ended September 30, 2025. The increase in revenue is primarily due to an increase in the number of SSi Mantra 3 surgical robotic systems, instruments sold and training income earned during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. 

 

42

 

 

Research and Development Expenses. Research and development expenses for the nine months ended September 30, 2026, were $5,891,960, as compared to $2,295,014 for the nine months ended September 30, 2025. The increase was primarily attributable to higher expenditures incurred in connection with clinical trials and related regulatory activities undertaken to support the Company’s efforts to obtain regulatory approvals, including FDA approval to market and CE Mark certification. The increase also reflects higher professional service fees associated with these regulatory initiatives, including regulatory consulting, clinical trial management, testing, documentation, and other compliance-related activities. Additionally, our continued to invest in enhancing the design and technological capabilities of its existing SSi Mantra system and expanding our product offerings.

 

Stock-based compensation expense. We had stock-based compensation expenses of $7,476,455 and $6,104,670 during the nine months ended September 30, 2026 and 2025, respectively. The increase in stock-based compensation expense was primarily attributable to the issuance of new Restricted Share Awards, as well the vesting of advisory shares during the current period, under our 2016 Stock Incentive Plan.

 

Depreciation and amortization expense. We had depreciation and amortization expense of $1,029,360 for nine months ended September 30, 2026, as compared to $766,416 for nine months ended September 30, 2025. The increase in depreciation and amortization expense was primarily attributable to an increase in fixed assets during the current period.

 

Selling, general and administrative expense. We incurred $13,165,885 in SG&A expense during the nine months ended September 30, 2026, as compared to $11,460,139 for the nine months ended September 30, 2025.

 

Our SG&A expense is comprised of expenses relating to salaries and benefits, retirement benefits as well as costs related to recruitment, other compensation expenses of sales and marketing and client management personnel, sales commission, travel and brand building, client events and conferences, training and retention of senior management and other support personnel in enabling functions, telecommunications, utilities, travel and other miscellaneous administrative costs. SG&A expenses also include legal and professional fees (which represent the costs of third party legal, tax, accounting, immigration and other advisors), investment in product development, digital technology, advanced automation and robotics, related to grants of our equity awards to members of our board of directors. The increase in SG&A expenses compared to the previous period is primarily due to higher legal and professional fees, and expenses incurred for business events held during the current period, which were not present in the previous period.

 

Other income, net. We have recognized $412,411 in interest income net for the nine months ended September 30, 2026, as compared to $3,817 during the nine months ended September 30, 2025. The increase was primarily attributable to higher interest income on sales and fixed deposits, together with nil interest expense on convertible notes, as such expense was incurred during the prior-year period. This increase was partially offset by higher interest expense relating to the utilization of working capital facilities availed from banks.

 

Income tax expense. For the nine months ended September 30, 2026, income tax expense was $452,369 as compared to $2,200,788 for the nine months ended September 30, 2025. The decrease is primarily due to a reduction in taxable profits generated from the Company’s Indian operations during the current period compared to the prior-year period.

 

Net Loss. We incurred a net loss of $12,025,620 for the nine months ended September 30, 2026, as compared to a net loss of $9,656,008 for the nine months ended September 30, 2025. The increase in net loss for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 is primarily the result of an increase in research & development expense of $3,596,946, SG&A expense of $1,705,746, stock-based compensation expense of $1,371,785, depreciation and amortization expense of $262,944 offset by an increase in the gross profit by $2,410,796 and decrease in income tax expense of $1,748,419.

 

Liquidity and Capital Resources

 

We expect to require substantial funds for scaling up our operations, incurring capital expenditure to have our own in-house machining and tooling capacity and to continue to finance our research and development work in the field of surgical robotics.

 

43

 

 

Cash Flow Summary:

 

   For the nine month ended 
Particulars  September 30,
2026
   September 30,
2025
 
Net cash provided by operating activities:        
Net loss  $(12,025,620)  $(9,656,008)
Non-cash adjustments   8,765,865    7,431,442 
Change in operating assets and liabilities   (9,655,426)   (14,798,851)
Net cash used in operating activities   (12,915,181)   (17,023,417)
Net cash used in investing activities   (1,701,323)   (1,944,527)
Net cash provided by financing activities   25,142,693    24,793,391 
Net change in cash   10,526,189    5,825,447 
Effect of exchange rate on cash   (1,524,276)   (409,735)
Cash at beginning of period   9,603,020    6,623,535 
Cash at end of period  $18,604,933   $12,039,247 

 

Cash Flows from Operating Activities

 

During the nine months ended September 30, 2026, net cash used in operating activities was $12,915,181 resulting from our net loss of $12,025,620 partially offset by non-cash charges of $8,765,865 primarily driven by depreciation charges, operating lease expense and stock-based compensation expense. We had cash used in our operating assets and liabilities of $9,655,426 primarily driven by increases in accounts receivables, prepaid and other assets, inventory and decrease in income taxes payable offset by increase in deferred revenue and accounts payable.

 

During the nine months ended September 30, 2025, net cash used in operating activities was $17,023,417 resulting from our net loss of $9,656,008 partially offset by non-cash charges of $7,431,442 primarily driven by depreciation charges, operating lease expense, Interest expense (net), Interest and other income, net, credit loss reserve, advisory share expense and other stock compensation expense. We had cash used in our operating assets and liabilities of $17,023,417 primarily driven by an increase in inventory, prepaid and other assets and accounts receivables offset by an increase in deferred revenue, accounts payable, accrued expenses, prepaids and other noncurrent assets, operating lease expense and other liabilities.

 

Cash Flows from Investing Activities

 

During the nine months ended September 30, 2026, we had net cash used in investing activities of $1,701,323 in purchase of property and equipment.

 

During the nine months ended September 30, 2025, we had net cash used in investing activities of $1,944,527 in purchase of property and equipment.

 

Cash Flows from Financing Activities

 

Net cash provided by financing activities was $25,142,693 for the nine months ended September 30, 2026, compared to $24,793,391 for the nine months ended September 30, 2025. Financing activities during the current period were primarily driven by net proceeds of $18,446,498 from a private placement completed in March 2026, and proceeds received from bank overdraft facility and term loan of $5,444,921 and $1,251,274 respectively.

 

During the nine months ended September 30, 2025, we had net cash provided by financing activities of $24,793,391, which comprised of proceeds of $28,000,000 from issuance of convertible notes to our principal stockholder and proceeds from our bank overdraft facility (net) by $2,074,877 offset by repayment of convertible notes to our principal stockholder and other investors amounting to $4,212,637 and $1,068,849 respectively.

 

44

 

 

Critical Accounting Policies

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

We consider the policies discussed below to be critical to an understanding of our condensed consolidated financial statements, as their application places the most significant demands on management’s judgment regarding matters that are inherently uncertain at the time an estimate is made.

 

These policies include fair value of stock options and standalone selling price in case of bundled revenue contracts.

 

These accounting policies, estimates and the associated risks are set out below. Future events may not develop exactly as forecasted and estimates routinely require adjustment.

 

Stock-based Compensation Expense

 

Under the fair value recognition provisions of ASC Topic 718, Compensation-Stock Compensation, cost is measured at the grant date based on the fair value of the award and is amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

 

Determining the fair value of stock-based awards at the grant date requires significant judgment, including estimating the expected term over which the stock awards will be outstanding before they are exercised and the expected volatility of our stock.

 

As of September 30, 2026, we have issued two types of equity incentives:

 

Stock Options: These provide employees with the right, but not the obligation, to purchase shares of our common stock at a specified price, within a defined period, as per the terms of the stock option agreement. Stock-based compensation expense associated with our 2016 Stock Incentive Plan and 2026 Incentive Stock Plan (adopted in April 2026) is measured at fair value using a Black-Scholes option-pricing model at commencement of each offering period and recognized over that offering period.

 

Restricted Stock Awards (“RSAs”): These do not require the employee to exercise any options. Each stock unit automatically converts into a specified number of shares upon vesting. We use the last three month’s average share price of common stock on OTC (prior to April 24, 2025) or on Nasdaq (subsequent to April 24, 2025) as grant date fair value for RSAs.

 

Standalone Selling Price

 

Our system sale arrangements contain multiple products and services, including system, accessories, instruments and services. Other than services, we generally deliver all of the products upfront. Each of these products and services is a distinct performance obligation. System, instruments, accessories and services are also sold on a standalone basis. For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling prices considering market conditions and entity-specific factors including, but not limited to, historical pricing data, features and functionality of the products and services and industry benchmark. We regularly review standalone selling prices and maintain internal controls over establishing and updating these estimates. Revenue that is allocated to the service obligation is deferred and recognized ratably over the service period upon expiration of first year of service which is free and included in the system sale arrangements.

 

45

 

 

Off-Balance Sheet Arrangements 

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Dr. Sudhir Srivastava, our Chairman, Chief Executive Officer and Interim Chief Financial Officer (our Principal Executive Officer, Principal Financial and Accounting Officer), evaluated the effectiveness of the design and operation of our disclosure controls and procedures and internal control over financial reporting, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2026.

 

To ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including Dr. Sudhir Srivastava, as our Principal Executive Officer, and Principal Financial and Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

 

Based on the evaluation performed as of September 30, 2026, as a result of the material weaknesses in internal control over financial reporting that are previously disclosed under “Part II - Item 9A - Controls and Procedures” in our Annual Report on Form 10-K for the year ended December 31, 2025, Dr. Sudhir Srivastava, as our Principal Executive, Financial and Accounting Officer determined that our disclosure controls and procedures were not effective as of such date in that:

 

  ● We failed to design adequate controls and procedures to provide reasonable assurance that U.S. GAAP was being properly applied to the matters resulting into the restatement of our quarterly financial statements, including recognition of revenue in case of deferred payment sales, recognition of right of use of certain assets and lease liabilities and functional and other classifications, also leading to certain accounting errors as described in details in the restatement notes as included in the respective amended quarterly financial statements.

 

46

 

 

  ● We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act.

 

  ● We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Remediation Plan

 

We have been addressing and remediating these material weaknesses with the support and assistance of the accounting and financial staff employed by our Indian operating subsidiary. We have enhanced the review process for significant transactions to ensure proper accounting treatment under applicable guidelines and have engaged the external experts to provide guidance to our staff in the areas of financial reporting, internal controls, and enterprise risk management and assist it in the application of accounting principles to complex transactions. This external expert group is also helping us in strengthening its existing internal controls, policies and Standard Operating Procedures (“SOPs”) in all the major functional areas.

 

In addition, we have also engaged services of external experts in the field of designing, development and implementation of a comprehensive cloud-based ERP system. The ERP implementation process involves a detailed process study of each of the business functions and engagement with their respective process owners, identifying their linkages with other business functions and designing report formats, data sourcing and customizing the ERP system and training of the respective teams to meet the business data flow and reporting requirements of each business function. Post completion of roll out of all the functional modules under this new cloud-based ERP system which is designed to integrate all business functions within the accounting and financial department would help us in further addressing the abovementioned weaknesses.

 

The Company does not expect that our disclosure controls or internal controls will prevent all errors and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of any control system is subject to resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the fact that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Controls Over Financial Reporting

 

Except for the remediation efforts described above, there were no changes in our internal controls over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

47

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

In addition to matters which have been reported in our previous periodic filings under the Securities Exchange Act of 1934, as amended, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

 

Item 1A. Risk Factors.

 

As a “smaller reporting company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the three months ended September 30, 2026, the Company issued an aggregate of 319,392 shares of common stock to advisors and a consultant in consideration of advisory and consulting services, including 116,400 shares issued in settlement of an outstanding liability for services rendered in prior periods, as described in Note 13 to the condensed consolidated financial statements included in this Quarterly Report. The shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions not involving a public offering. No underwriters were involved and no cash proceeds were received.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable

 

Item 5. Other Information.

 

During the three months ended September 30, 2026, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K. 

 

Item 6. Exhibits.

 

Exhibit No.   Description of Exhibit
31.1   Section 302 Certification – Chief Executive Officer and Chief Financial Officer(1)
32.1   Section 906 Certification – Chief Executive Officer and Chief Financial Officer(1)
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

(1) Filed herewith.

 

* Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under those sections.

 

48

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

 

Dated: November 16, 2026 SS INNOVATIONS INTERNATIONAL, INC.
   
  By: /s/ Sudhir Prem Srivastava
    Sudhir Prem Srivastava, M.D.
    Chairman, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive, Financial and Accounting Officer)

 

49

 

Keep reading